tegafur and Adenocarcinoma studies

Research Excerpts

Excerpt	Relevance	Reference
"The effect of postoperative tegafur-uracil on overall survival (OS) after resection of stage I adenocarcinoma has been shown in clinical trials."	9.69	Postoperative tegafur-uracil for stage I lung adenocarcinoma: first real-world data with an exploratory subgroup analysis. ( Aoyama, A; Date, H; Date, N; Fujinaga, T; Fukada, T; Hamaji, M; Huang, CL; Ishikawa, M; Katakura, H; Kayawake, H; Kobayashi, M; Kono, T; Matsumoto, A; Menju, T; Miyahara, R; Miyamoto, E; Miyata, R; Morita, S; Nakagawa, T; Nakakura, A; Okumura, N; Sakaguchi, Y; Sakai, H; Shimazu, Y; Sonobe, M; Sumitomo, R; Takahashi, M, 2023)
"To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC)."	9.41	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. ( Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y, 2021)
"Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)."	9.27	S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018)
"The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma."	9.22	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. ( Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H, 2016)
"This study aimed to determine the maximum tolerated dose and the recommended dose of combining S-1 with gemcitabine and cisplatin for advanced biliary tract adenocarcinoma first-line therapy."	9.22	Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H, 2016)
"Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites."	9.22	Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. ( Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N, 2016)
"The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint."	9.20	A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015)
"A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)."	9.20	Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015)
"The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy."	9.20	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015)
"Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites."	9.19	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014)
"A phase I dose-escalation study was performed to investigate the safety and pharmacokinetics of the combination of S-1 and gefitinib in patients with pulmonary adenocarcinoma who had failed previous chemotherapy."	9.17	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ( Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N, 2013)
"This study evaluated long-term outcomes for patients who received adjuvant gemcitabine plus S-1 chemotherapy after resection for pancreatic carcinoma."	9.16	Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2012)
"In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI."	9.16	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012)
"We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)."	9.16	Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012)
" This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy."	9.15	A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. ( Chen, YM; Chou, KT; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH, 2011)
"This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer."	9.15	Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011)
"A 24-hour infusion of irinotecan combined with UFT/LV is feasible and active for metastatic colorectal cancer."	9.14	Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009)
"Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile."	9.14	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010)
"We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11)."	9.14	Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N, 2010)
"Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer."	9.14	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010)
"The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer."	9.14	Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T, 2010)
"A randomized controlled trial was conducted to determine whether pathologic necrosis in response to preoperative treatment with uracil-tegafur(UFT) could be used to identify patients with colorectal cancer most likely to benefit from postoperative adjuvant therapy with the drug."	9.13	Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. ( Fujii, M; Kochi, M; Takayama, T, 2008)
"Tegafur-uracil (UFT) plus leucovorin (LV, folinic acid) with alternating irinotecan and oxaliplatin were effective and well tolerated in patients with metastatic colorectal cancer (mCRC) in a phase I study."	9.13	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G, 2008)
"A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer."	9.12	Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006)
"To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer."	9.12	Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007)
"We randomly assigned patients with completely resected pathological stage I adenocarcinoma of the lung to receive either oral uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years or no treatment."	9.11	A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Hamajima, N; Hata, E; Ichinose, Y; Kato, H; Ohta, M; Tada, H; Tsuboi, M; Tsubota, N; Wada, H; Watanabe, Y, 2004)
"To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis."	9.11	Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004)
" infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC)."	9.11	Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. ( Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E, 2005)
"The aim of this study was to evaluate the efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma (T3-T4) when delivered in combination with chemotherapy (oral tegafur-uracil modulated with leucovorin)."	9.10	Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. ( Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002)
"A prospective randomized multi-center study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of futraful (FT) and tamoxifen (TAM) for postoperative adjuvant therapy for stage II breast cancer after curative surgery."	9.10	Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer. ( Asaishi, K; Hata, Y; Hirata, K; Kato, H; Okazaki, M; Okushiba, S; Takahashi, H; Todo, S; Uchino, J, 2003)
"The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or metastatic colorectal cancer."	9.10	A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ( Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M, 2003)
"To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-ftorafur, etoposide, and leucovorin for metastatic breast cancer."	9.10	Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. ( Carlson, RW; Grekowicz, A; Hartman, AR; Lum, BL; Schurman, C; Shapiro, R; Sikic, BI; Stockdale, FE, 2003)
") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options."	9.10	Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002)
" To date, the evidence regarding the preoperative apatinib plus S-1 for locally advanced pulmonary adenocarcinoma is scarce."	9.05	Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature. ( Liu, D; Wang, X; Yang, DP; Zhang, C; Zhang, M, 2020)
"A 42-year-old woman with reversible splenial lesion syndrome (RESLES) and rectal adenocarcinoma presented with sudden-onset delirium after the sixth cycle of her chemotherapy drug, oral tegafur-uracil (300 mg/m/day, days 1-14, with treatment cycle repeated every 21 days)."	7.96	Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma. ( Bi, QQ; Chen, YJ; Ge, YX; Lin, YY, 2020)
"Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades."	7.88	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018)
"Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung."	7.85	The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung. ( Hamada, C; Kato, H; Ohta, M; Tsuboi, M, 2017)
"When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis."	7.83	Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016)
"This study investigated the clinical efficacy and toxicity of the combination chemotherapy using S-1 plus irinotecan for esophageal adenocarcinoma."	7.78	A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. ( Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y, 2012)
"To identify useful predictive factors for the response to 5-fluorouracil (5-FU)/leucovorin (LV) and oral uracil and tegafur (UFT)/LV chemotherapy among patients with colorectal cancer, we investigated the association between the gene expression levels of pyrimidine and folate metabolism-related enzymes in colorectal cancer (CRC) tissues and the response to UFT/LV neoadjuvant chemotherapy."	7.78	Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. ( Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2012)
"5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma."	7.76	A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010)
" The aim of this study was to determine the effect of adjuvant gemcitabine and S-1 therapy for patients with adenocarcinoma of the body or tail of the pancreas who had undergone surgical resection by distal pancreatectomy."	7.75	Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2009)
"A 59-year-old man diagnosed as gastric cancer with peritonitis carcinomatosa was treated with paclitaxel and TS-1; 60 mg/m(2)/day of paclitaxel was given on days 1 and 8, and 60-80 mg/m(2)/day of TS-1 was given for 2 weeks."	7.75	Advanced gastric cancer patient with peritonitis carcinomatosa successfully treated with a combination therapy of paclitaxel and TS-1, but relapsed with multiple bone metastasis and died from rapidly progressive meningitis carcinomatosa--advanced gastric ( Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T; Yoneoka, Y, 2009)
"Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas."	7.74	Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007)
"We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1."	7.74	Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007)
"Patients admitted for curative surgery for pancreatic adenocarcinoma received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks."	7.74	Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2008)
"A 71-year-old man who had undergone surgery for stage II adenocarcinoma of the lung followed by adjuvant tegafur-uracil (UFT; 300 mg/day) therapy was admitted."	7.73	Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery. ( Endo, S; Hasegawa, T; Saito, N; Sato, Y; Sohara, Y, 2005)
"We report a case in which TS-1 + paclitaxel (PTX) administration was effective for gastric cancer with malignant ascites."	7.73	[Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report]. ( Ikuta, Y; Kobayashi, H; Sugihara, S; Teshima, K; Toyama, E; Tsuruta, Y; Yonemitsu, K, 2005)
" He had nausea, vomiting and anorexia due to pyloric stenosis, and was treated with 600 mg of UFT E granules/day orally for 5 consecutive days followed by 2 drug-free days (weekly-5 method), and 2 mg of lentinan intravenously twice a week."	7.70	[A case of advanced gastric cancer (type 3) with pyloric stenosis, multiple liver and lymph node metastases responding to UFT-E granules and lentinan]. ( Kondo, M; Takahashi, S; Takemura, T; Yoshikawa, T, 2000)
"Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)."	7.67	Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984)
"The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity."	7.67	Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. ( Hoshi, A; Iigo, M; Kitagawa, H, 1986)
"A significant inhibition of the growth of adenocarcinoma 755 tumors in BDF1 mice was effected by oral tegafur (FT) in combination with oral (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd), at doses at which neither drug used alone had antitumor activity."	7.67	The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2'-deoxyuridine. ( De Clercq, E; Hoshi, A; Iigo, M; Nishimura, S; Yamaizumi, Z, 1987)
"A 36-year-old woman was treated with tamoxifen for lung metastasis of breast cancer and had marked hyperlipoproteinemia with giant fatty liver, high plasma triglyceride levels (3673 mg/dl), and increased levels of very low density lipoprotein (VLDL) and intermediate density lipoprotein (UDL)."	7.67	[A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen]. ( Kitabayashi, K; Koshino, Y; Mabuchi, H; Miyazaki, I; Nakano, Y; Noguchi, M; Nonomura, A; Tajiri, K; Taniya, T, 1987)
"When combined with bromovinyldeoxyuridine (BVdUrd), 5-fluorouracil (FUra) brought about a significant reduction in the growth of adenocarcinoma 755 tumors in mice, at doses at which either drug used alone (BVdUrd: 100 mg/kg) did not effect an appreciable antitumor activity."	7.67	Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1987)
"Grade 3 neutropenia was common (35%)."	6.90	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019)
"4%) and renal adverse events (all grades: CS, 18."	6.78	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."	6.74	Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
"Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)."	6.74	A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009)
"Apatinib has been proven to significantly prolong the survival of the patients with advanced chemotherapy-refractory gastric cancer."	6.66	S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. ( Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020)
"The effect of postoperative tegafur-uracil on overall survival (OS) after resection of stage I adenocarcinoma has been shown in clinical trials."	5.69	Postoperative tegafur-uracil for stage I lung adenocarcinoma: first real-world data with an exploratory subgroup analysis. ( Aoyama, A; Date, H; Date, N; Fujinaga, T; Fukada, T; Hamaji, M; Huang, CL; Ishikawa, M; Katakura, H; Kayawake, H; Kobayashi, M; Kono, T; Matsumoto, A; Menju, T; Miyahara, R; Miyamoto, E; Miyata, R; Morita, S; Nakagawa, T; Nakakura, A; Okumura, N; Sakaguchi, Y; Sakai, H; Shimazu, Y; Sonobe, M; Sumitomo, R; Takahashi, M, 2023)
"All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively."	5.48	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018)
"To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC)."	5.41	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. ( Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y, 2021)
"We present here a 23-year-old gastric cancer patient who first presented with right-side testis swelling and pain."	5.36	The unusual presentation of gastric adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral tegafur/uracil and leucovorin. ( Chao, Y; Kuo, JY; Lee, RC; Li, AF; Li, CP; Luo, JC; Yang, KC, 2010)
"Uracil/tegafur was stopped in December 10, 2005, and docetaxel (taxotere) 50mg/m2 was given in December 12, 2005."	5.34	[Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer]. ( Bandoh, S; Kanaji, N, 2007)
"A 38-year-old female patient with gastric cancer, of which histological type was a poorly differenciated adenocarcinoma and a clinical finding was T3N1MO (Stage IIIA), underwent total gastrectomy with D2 lymphadenectomy as the surgical treatment."	5.33	[A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer]. ( Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K, 2006)
"Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)."	5.27	S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018)
"The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma."	5.22	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. ( Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H, 2016)
"This study aimed to determine the maximum tolerated dose and the recommended dose of combining S-1 with gemcitabine and cisplatin for advanced biliary tract adenocarcinoma first-line therapy."	5.22	Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer. ( Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H, 2016)
"Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites."	5.22	Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. ( Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N, 2016)
"The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint."	5.20	A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015)
"A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)."	5.20	Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015)
"The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy."	5.20	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015)
" This study investigated the impact of KRAS, NRAS, BRAF, PI3KCA and TP53 status on outcome of elderly metastatic colorectal cancer patients enrolled in TEGAFOX-E (cetuximab, oxaliplatin and oral uracil/ftorafur--UFT) phase II study."	5.19	Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. ( Bajetta, E; Beretta, E; Bertan, C; Biondani, P; Carbone, C; Di Bartolomeo, M; Dotti, KF; Lampis, A; Passalacqua, R; Perrone, F; Pietrantonio, F; Pilotti, S; Rimassa, L, 2014)
"Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites."	5.19	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014)
"The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs."	5.19	Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014)
"A phase I dose-escalation study was performed to investigate the safety and pharmacokinetics of the combination of S-1 and gefitinib in patients with pulmonary adenocarcinoma who had failed previous chemotherapy."	5.17	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. ( Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N, 2013)
"This study evaluated long-term outcomes for patients who received adjuvant gemcitabine plus S-1 chemotherapy after resection for pancreatic carcinoma."	5.16	Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2012)
"In Japan, a study comparing the effectiveness and safety of irinotecan plus S-1 (IRIS) with those of a combination of 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as second-line treatment in patients with advanced or recurrent colorectal cancer demonstrated that IRIS was non-inferior to FOLFIRI."	5.16	Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. ( Fukushima, H; Hatanaka, K; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Munakata, M; Nakamura, M; Nakatsumi, H; Sakata, Y; Sogabe, S; Tateyama, M; Yuki, S, 2012)
"We evaluated the efficacy and safety of a combination of S-1 and cisplatin (SP) versus gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract adenocarcinoma (ABTA)."	5.16	Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. ( Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW, 2012)
" This study aimed to assess the efficacy of adding daily oral UFT to gefitinib treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy."	5.15	A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. ( Chen, YM; Chou, KT; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH, 2011)
"This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer."	5.15	Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011)
"A 24-hour infusion of irinotecan combined with UFT/LV is feasible and active for metastatic colorectal cancer."	5.14	Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Suzuki, T; Tanaka, A, 2009)
"Patients were eligible for the study if they had histologically documented gastric adenocarcinoma previously treated with paclitaxel and cisplatin, age > or = 18 years, Eastern Clinical Oncology Group performance status < or =2, adequate organ function, and no evidence of gastrointestinal obstruction or passage disturbance."	5.14	Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Lee, SJ; Shim, HJ; Yoon, JY, 2009)
" We enrolled patients aged 20-75 years or younger, who had histologically proven gastric adenocarcinoma, and randomly assigned them by minimisation to receive either: a continuous infusion of fluorouracil (800 mg/m(2) per day, on days 1-5) every 4 weeks (n=234); intravenous irinotecan (70 mg/m(2), on days 1 and 15) and cisplatin (80 mg/m(2), on day 1) every 4 weeks (n=236); or oral S-1 (40 mg/m(2), twice a day, on days 1-28) every 6 weeks (n=234)."	5.14	Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. ( Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S, 2009)
"Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile."	5.14	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010)
"We carried out this study to examine the health-related quality of life (HRQOL) of patients with advanced colorectal cancer treated with the oral fluoropyrimidine S-1 plus irinotecan (CPT-11)."	5.14	Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Tsunoda, Y; Watanabe, M; Yasuda, N, 2010)
"Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer."	5.14	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010)
"The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer."	5.14	Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Futami, K; Kinugawa, N; Kusaba, H; Mibu, R; Mitsugi, K; Nakano, S; Sakai, K; Tanaka, R; Tanaka, S; Ueki, T, 2010)
"Eligibility criteria were histologically proven pancreatic adenocarcinoma with confirmation of progressive disease while receiving gemcitabine-based first-line chemotherapy, 20-74 years of age, Karnofsky performance status of 80-100 points, with measurable metastatic lesions, adequate hematological, renal and liver functions, and written informed consent."	5.14	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H, 2009)
"A randomized controlled trial was conducted to determine whether pathologic necrosis in response to preoperative treatment with uracil-tegafur(UFT) could be used to identify patients with colorectal cancer most likely to benefit from postoperative adjuvant therapy with the drug."	5.13	Clinical identification of colorectal cancer patients benefiting from adjuvant uracil-tegafur (UFT): a randomized controlled trial. ( Fujii, M; Kochi, M; Takayama, T, 2008)
"Tegafur-uracil (UFT) plus leucovorin (LV, folinic acid) with alternating irinotecan and oxaliplatin were effective and well tolerated in patients with metastatic colorectal cancer (mCRC) in a phase I study."	5.13	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. ( Craven, O; Palmer, K; Saunders, MP; Sheikh, HY; Sjursen, A; Swindell, R; Valle, JW; Waddell, T; Wilson, G, 2008)
"Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received UFT/leucovorin, carboplatin, and paclitaxel with RT (1."	5.13	A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma. ( Bendell, JC; Cohen, DP; Czito, BG; D'Amico, TA; Hurwitz, HI; Kelsey, CR; Lockhart, AC; Petros, WP; Truax, R; Willett, CG, 2008)
"A combination of irinotecan with continuous intravenous infusions of 5-fluorouracil (5-FU) and leucovorin (LV) is often used to treat advanced colorectal cancer."	5.12	Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. ( Goto, A; Hamaguchi, T; Kato, K; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yasui, H, 2006)
"To evaluate the tolerability and effectiveness of uracil-tegafur (UFT) with leucovorin (LV) in the treatment of elderly patients with advanced colorectal cancer."	5.12	Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299. ( Beatty, PA; Benson, AB; Hochster, HS; Luo, W; Lyman, BT; Mulcahy, M; Popa, EC, 2007)
"We randomly assigned patients with completely resected pathological stage I adenocarcinoma of the lung to receive either oral uracil-tegafur (250 mg of tegafur per square meter of body-surface area per day) for two years or no treatment."	5.11	A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Hamajima, N; Hata, E; Ichinose, Y; Kato, H; Ohta, M; Tada, H; Tsuboi, M; Tsubota, N; Wada, H; Watanabe, Y, 2004)
"To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis."	5.11	Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004)
" This phase II study assessed the response rate and toxicity profile of the combination of epirubicin, cisplatin and UFT in patients with metastatic adenocarcinoma of the stomach."	5.11	A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma. ( Byun, JH; Choi, MG; Chung, IS; Hong, YS; Kang, JH; Kim, KW; Lee, KS; Lee, MA; Moon, DH; Park, SY; Shim, BY; Woo, IS, 2005)
" infusion; days 1, 8 and 15) combined with UFT (oral combination of tegafur and uracil) 200 mg/m2/day plus leucovorin (LV) 45 mg/m2/day (both divided into three separate oral doses every 8 h, days 1-21) every 4 weeks as first-line chemotherapy of metastatic colorectal cancer (CRC)."	5.11	Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer. ( Alfonso, PG; Castañon, C; Cerezuela, P; Cruz, JJ; González, E; López-Mateos, Y; Méndez, M; Pujol, E, 2005)
"A phase II study was performed to evaluate the clinical efficacy and toxicity of oxaliplatin combined with uracil and tegafur (UFT) in patients with advanced colorectal cancer previously treated with a fluoropyrimidine-based regimen."	5.10	Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer. ( Chun, H; Im, YH; Jung, CW; Kang, WK; Kim, JH; Kim, K; Kim, WS; Lee, HR; Lee, JY; Lee, MH; Lee, NS; Lee, WY; Nam, E; Oh, SY; Park, CH; Park, JO; Park, K; Park, SH; Song, SY, 2002)
"The aim of this study was to evaluate the efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma (T3-T4) when delivered in combination with chemotherapy (oral tegafur-uracil modulated with leucovorin)."	5.10	Efficacy of preoperative radiation therapy for resectable rectal adenocarcinoma when combined with oral tegafur-uracil modulated with leucovorin: results from a phase II study. ( Batlle, JF; Carpeño, Jde C; García, AG; Grande, AG; Juberías, AM; Olivar, LM; Piñeiro, EH; Sánchez Santos, ME; Uzcudun, AE; Velasco, JC, 2002)
"The objectives of this study were to evaluate the efficacy and toxicity of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur (UFT) in patients with advanced adenocarcinoma of the pancreas."	5.10	Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. ( Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE, 2002)
"A prospective randomized multi-center study was undertaken for 2 years and 3 months from November 1982, with the aim of examining the significance of using a combination of futraful (FT) and tamoxifen (TAM) for postoperative adjuvant therapy for stage II breast cancer after curative surgery."	5.10	Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer. ( Asaishi, K; Hata, Y; Hirata, K; Kato, H; Okazaki, M; Okushiba, S; Takahashi, H; Todo, S; Uchino, J, 2003)
"The aim of this study was to determine the maximum tolerated dose (MTD), toxicity profile and response rate of the oral 5-fluorouracil prodrug UFT (tegafur/uracil) and leucovorin (LV) in combination with irinotecan in patients with advanced or metastatic colorectal cancer."	5.10	A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. ( Bailey, SM; Campbell, S; Cunningham, D; Glasspool, R; Hill, M; Macham, MA; Mackay, HJ; Martin, C; Massey, A; Price, T; Twelves, C; Uzzel, M, 2003)
"To determine the maximum tolerated doses, toxicities, and therapeutic effect of an oral chemotherapy regimen consisting of uracil-ftorafur, etoposide, and leucovorin for metastatic breast cancer."	5.10	Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer. ( Carlson, RW; Grekowicz, A; Hartman, AR; Lum, BL; Schurman, C; Shapiro, R; Sikic, BI; Stockdale, FE, 2003)
") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options."	5.10	Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002)
"The purpose of this study is to evaluate the efficacy of postoperative adjuvant chemotherapy using uracil and tegafur (UFT) for colorectal cancer."	5.10	Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. ( Baba, S; Hasumi, A; Kato, T; Koike, A; Manabe, T; Maruta, M; Miura, K; Nakazato, H; Nimura, Y; Ohashi, Y; Saji, S; Suzuki, H; Takagi, H; Yamaguchi, A, 2002)
"Two studies were carried out to determine the activity and evaluate the toxicity of oral chemotherapy with uracil and tegafur in a 4:1 molar ratio (UFT) plus or minus calcium folinate in elderly patients with advanced colorectal cancer."	5.09	UFT plus or minus calcium folinate for metastatic colorectal cancer in older patients. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Díáz-Rubio, E; Fernández Martos, C; Gallén, M; Marcuello, E; Massuti, T; Navarro, M; Rifá, J; Sastre, J, 1999)
"Oxaliplatin is a unique platinum compound with single-agent activity in both chemotherapy-naïve colorectal cancer patients and patients who progressed on 5-fluorouracil (5-FU)."	5.09	Oxaliplatin and UFT/oral calcium folinate for advanced colorectal carcinoma. ( Hoff, PM; Pazdur, R, 1999)
"To determine whether long-term oral administration of UFT, a combination of 5-fluorouracil and uracil, in addition to conventional estrogen therapy improved the response and survival of the patients with advanced stage D2 prostate adenocarcinoma, a randomized prospective study was performed with either estrogen alone (Honvan 200 mg/day or presexol 1 mg/day: group A) or estrogen plus UFT (400 mg/day:group B)."	5.08	[Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)]. ( Fujii, H; Fukushima, S; Harada, M; Hosaka, M; Kondo, I; Kubota, Y; Miura, T, 1996)
"In this prospective randomized study the effect of oral Ftorafur was compared with that of intravenous 5-fluorouracil in patients with advanced adenocarcinoma of the stomach, colon or rectum."	5.06	Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. ( Bjerkeset, T; Fjøsne, HE, 1986)
" To date, the evidence regarding the preoperative apatinib plus S-1 for locally advanced pulmonary adenocarcinoma is scarce."	5.05	Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature. ( Liu, D; Wang, X; Yang, DP; Zhang, C; Zhang, M, 2020)
"In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)."	5.04	[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979)
" On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan."	4.83	[Adjuvant chemotherapy for non-small cell lung cancer]. ( Ichinose, Y; Okamoto, T, 2006)
" In Japan, the adjuvant use of tegafur/uracil has been recommended for stage Ⅰ and Ⅱ adenocarcinoma with a tumor diameter of more than 2 cm."	3.96	[Current Status of Perioperative Chemotherapy for Lung Cancer]. ( Watanabe, S; Yotsukura, M, 2020)
"A 42-year-old woman with reversible splenial lesion syndrome (RESLES) and rectal adenocarcinoma presented with sudden-onset delirium after the sixth cycle of her chemotherapy drug, oral tegafur-uracil (300 mg/m/day, days 1-14, with treatment cycle repeated every 21 days)."	3.96	Reversible Splenial Lesion Syndrome (RESLES) After Chemotherapy of Oral Tegafur-uracil in a Female With Locally Rectal Adenocarcinoma. ( Bi, QQ; Chen, YJ; Ge, YX; Lin, YY, 2020)
"Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades."	3.88	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018)
"Tegafur-uracil (UFT) improves survival in patients with stage I adenocarcinoma of the lung."	3.85	The Effect of Tegafur-Uracil on Survival in T Categories as Defined in the Eighth Edition of the TNM Classification: An Exploratory Analysis of Postoperative Adjuvant Tegafur-Uracil on Survival in Patients with Adenocarcinoma of the Lung. ( Hamada, C; Kato, H; Ohta, M; Tsuboi, M, 2017)
"Objective To explore the efficacy and toxicities of gemcitabine combined with S-1 in treating locally advanced and metastatic pancreatic ductal adenocarcinoma and prognostic factors."	3.85	Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer. ( Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N, 2017)
"When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis."	3.83	Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016)
"236 patients with a completely resected NSCLC (adenocarcinoma and squamous cell carcinoma) of pathological stage IA (maximum tumor diameter of 2 cm or greater), IB, and II tumors were given a dose of 250 mg of uracil-tegafur per square meter of body surface area per day orally for two years after surgery."	3.81	Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan. ( Abiko, T; Eguchi, K; Hashizume, T; Horio, H; Kato, R; Kawamura, M; Kobayashi, K; Matsutani, N; Nakayama, M; Oyama, T; Sawafuji, M; Tajima, A, 2015)
"Patients with primary, resectable, T2 or T3, N0-N1 adenocarcinoma in the lower 6 cm of the rectum were given chemoradiotherapy (60 Gy in 30 fractions to tumour, 50 Gy in 30 fractions to elective lymph node volumes, 5 Gy endorectal brachytherapy boost, and oral tegafur-uracil 300 mg/m(2)) every weekday for 6 weeks."	3.81	High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. ( Appelt, AL; Harling, H; Jakobsen, A; Jensen, FS; Jensen, LH; Jørgensen, JC; Lindebjerg, J; Pløen, J; Rafaelsen, SR, 2015)
"This study investigated the clinical efficacy and toxicity of the combination chemotherapy using S-1 plus irinotecan for esophageal adenocarcinoma."	3.78	A pilot trial of S-1 plus irinotecan chemotherapy for esophageal adenocarcinoma. ( Fujiwara, N; Hoshino, A; Jirawat, S; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Ohta, S; Okada, T; Ryotokuji, T; Tokairin, Y, 2012)
"To identify useful predictive factors for the response to 5-fluorouracil (5-FU)/leucovorin (LV) and oral uracil and tegafur (UFT)/LV chemotherapy among patients with colorectal cancer, we investigated the association between the gene expression levels of pyrimidine and folate metabolism-related enzymes in colorectal cancer (CRC) tissues and the response to UFT/LV neoadjuvant chemotherapy."	3.78	Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. ( Nagase, H; Okada, K; Sadahiro, S; Suzuki, T; Tanaka, A; Uchida, J, 2012)
"A total of 123 patients with unresectable or recurrent gastric adenocarcinoma with peritoneal metastasis receiving intravenous and intraperitoneal paclitaxel combined with S-1 were retrospectively studied."	3.78	Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis. ( Emoto, S; Hirano, K; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Yamaguchi, H; Yamamoto, N, 2012)
"5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma."	3.76	A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010)
" We describe a patient with acute abdominal symptoms and evidence of PCI with PBG under cetuximab, oxaliplatin, tegafur-uracil and folinic acid chemotherapy for metastatic adenocarcinoma of the rectosigmoid junction."	3.76	Gas in portal circulation and pneumatosis cystoides intestinalis during chemotherapy for advanced rectal cancer. ( Astone, A; Barone, C; Chiarla, C; Clemente, G; De Rose, AM; Giovannini, I; Nuzzo, G, 2010)
" The aim of this study was to determine the effect of adjuvant gemcitabine and S-1 therapy for patients with adenocarcinoma of the body or tail of the pancreas who had undergone surgical resection by distal pancreatectomy."	3.75	Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2009)
"A 59-year-old man diagnosed as gastric cancer with peritonitis carcinomatosa was treated with paclitaxel and TS-1; 60 mg/m(2)/day of paclitaxel was given on days 1 and 8, and 60-80 mg/m(2)/day of TS-1 was given for 2 weeks."	3.75	Advanced gastric cancer patient with peritonitis carcinomatosa successfully treated with a combination therapy of paclitaxel and TS-1, but relapsed with multiple bone metastasis and died from rapidly progressive meningitis carcinomatosa--advanced gastric ( Hasegawa, K; Hirono, H; Shibasaki, K; Soga, K; Watanabe, T; Yoneoka, Y, 2009)
"The subjects consisted of 23 patients with pancreatic adenocarcinoma who had liver metastases and were treated with S-1 and gemcitabine as the first-line treatment."	3.74	Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis. ( Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O, 2008)
" Actually, the EGFR tyrosine kinase inhibitor, gefitinib, is well known to be significantly effective for oriental people, including Japanese, female, adenocarcinoma and never-smoker, suggesting an inherited difference."	3.74	[Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan]. ( Hanibuchi, M; Sone, S; Tomimoto, H; Yano, S, 2007)
"Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas."	3.74	Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007)
"We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1."	3.74	Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer. ( Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2007)
"Although postoperative adjuvant chemotherapy (PAC) with uracil-tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11."	3.74	Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. ( Akimoto, S; Fukui, Y; Gong, Y; Guo, R; Hirano, T; Inada, H; Kato, H; Kawakami, T; Kojika, M; Maeda, J; Mukai, K; Nawa, K; Ogiwara, A; Ohira, T; Oka, T; Suga, Y, 2008)
"Patients admitted for curative surgery for pancreatic adenocarcinoma received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks."	3.74	Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2008)
"A 71-year-old man who had undergone surgery for stage II adenocarcinoma of the lung followed by adjuvant tegafur-uracil (UFT; 300 mg/day) therapy was admitted."	3.73	Pulmonary cryptococcosis mimicking pulmonary metastases in a patient treated with Tegafur-uracil after lung cancer surgery. ( Endo, S; Hasegawa, T; Saito, N; Sato, Y; Sohara, Y, 2005)
"We report a case in which TS-1 + paclitaxel (PTX) administration was effective for gastric cancer with malignant ascites."	3.73	[Effective TS-1+paclitaxel administration for gastric cancer with malignant ascites--a case report]. ( Ikuta, Y; Kobayashi, H; Sugihara, S; Teshima, K; Toyama, E; Tsuruta, Y; Yonemitsu, K, 2005)
"We treated a patient with inoperable advanced gastric cancer and malignant ascites by combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)."	3.72	[A patient with advanced gastric cancer that response remarkably to combination chemotherapy of TS-1 and biweekly paclitaxel (TXL)]. ( Funai, S; Hirai, T; Kamei, A; Ohtsuka, H; Shindo, K; Shiozaki, H; Tanaka, A; Yoshifuji, T, 2003)
"One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT."	3.71	[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002)
"A patient with stage IVb advanced gastric cancer, who was Group 4 lymph node metastasis positive, underwent two postoperative courses of low-dose CDDP-tegafur therapy (800 mg/body/day of tegafur + 5 mg/body/5 administrations, 2 days of rest, of cisplatin)."	3.70	[Case of stage IVb gastric cancer in which favorable anti-tumor effect and good QOL were observed due to UFTP therapy after low-dose CDDP-tegafur therapy]. ( Fujino, R; Hayashi, N; Hirose, Y; Matsumura, M; Nagano, T; Oshita, M; Otsuka, T; Sumitomo, M; Takai, S; Taki, S, 1999)
" He had nausea, vomiting and anorexia due to pyloric stenosis, and was treated with 600 mg of UFT E granules/day orally for 5 consecutive days followed by 2 drug-free days (weekly-5 method), and 2 mg of lentinan intravenously twice a week."	3.70	[A case of advanced gastric cancer (type 3) with pyloric stenosis, multiple liver and lymph node metastases responding to UFT-E granules and lentinan]. ( Kondo, M; Takahashi, S; Takemura, T; Yoshikawa, T, 2000)
"The relationship between augmentation of cytotoxic activity of 5-fluorouracil (FUra) by l-leucovorin (l-LV) and combination schedule was investigated using human colon adenocarcinoma KM 20 C cell line."	3.69	[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. ( Okabe, H; Takeda, S; Toko, T; Unemi, N; Yuasa, C, 1995)
"We administered a slow-release formulation of tegafur (SF-SP) to a patient with cancer of the tongue."	3.69	[A case of tongue cancer effectively treated with tegafur]. ( Asakura, S; Fujibayashi, T; Fukuda, M; Imai, Y; Nagashima, T; Sakamoto, H; Sasaki, T; Shimada, I; Shinohara, M; Yokokura, Y, 1995)
" A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats."	3.69	Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997)
"A 34-year-old female patient with breast cancer metastasizing to bone had a remission after a course of treatment with medroxyprogesterone acetate (MPA) 1,200 mg/day, but again had a metastasis to the lungs."	3.68	[A case of bone and lung metastasis of breast cancer successfully treated with radiotherapy, chemotherapy and endocrine therapy]. ( Harada, N; Kanda, K; Kida, H; Narita, K; Uchimura, M; Waki, S, 1990)
"Twenty-six patients with advanced bronchogenic adenocarcinoma or large cell carcinoma were treated by combination chemotherapy consisting of Ftorafur, adriamycin and mitomycin C (FAM II)."	3.67	Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma. ( Cruciani, AR; De Marinis, A; Nunziati, F; Portalone, L; Salvati, F, 1984)
"A phase II evaluation of UFT, a mixture of tegafur and uracil, was performed in 13 patients with non-small cell lung cancer (eight patients with adenocarcinoma and five patients with squamous cell carcinoma)."	3.67	[A phase II study of UFT in non-small cell lung cancer]. ( Hojo, F; Inoue, I; Kimura, K; Nakamura, Y; Nakanishi, S; Noda, Y; Shimizu, E; Sone, S; Yagi, M; Yamasaki, K, 1986)
"The combined effects of X-ray irradiation and 5-FU derivatives (5-FU, tegafur, HCFU) treatment were investigated in mouse adenocarcinoma-755."	3.67	[Combined effects of radiation and 5-FU derivatives]. ( Dokiya, T; Hashimoto, S; Kunieda, E; Miyamoto, H; Shigematsu, N; Tominaga, J, 1986)
"The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity."	3.67	Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. ( Hoshi, A; Iigo, M; Kitagawa, H, 1986)
"A significant inhibition of the growth of adenocarcinoma 755 tumors in BDF1 mice was effected by oral tegafur (FT) in combination with oral (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd), at doses at which neither drug used alone had antitumor activity."	3.67	The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2'-deoxyuridine. ( De Clercq, E; Hoshi, A; Iigo, M; Nishimura, S; Yamaizumi, Z, 1987)
"A 36-year-old woman was treated with tamoxifen for lung metastasis of breast cancer and had marked hyperlipoproteinemia with giant fatty liver, high plasma triglyceride levels (3673 mg/dl), and increased levels of very low density lipoprotein (VLDL) and intermediate density lipoprotein (UDL)."	3.67	[A case report of hyperlipemia with giant fatty liver during adjuvant endocrine therapy by tamoxifen]. ( Kitabayashi, K; Koshino, Y; Mabuchi, H; Miyazaki, I; Nakano, Y; Noguchi, M; Nonomura, A; Tajiri, K; Taniya, T, 1987)
"When combined with bromovinyldeoxyuridine (BVdUrd), 5-fluorouracil (FUra) brought about a significant reduction in the growth of adenocarcinoma 755 tumors in mice, at doses at which either drug used alone (BVdUrd: 100 mg/kg) did not effect an appreciable antitumor activity."	3.67	Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1987)
"Twenty-five adult patients with adenocarcinoma of unknown primary origin were treated with oral tegafur followed by the combination of cyclophosphamide/adriamycin/cis-diamminedichloroplatinum(II) (CAP) if they failed to respond to tegafur."	3.66	Sequential chemotherapy for adenocarcinoma of unknown primary. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
"Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled."	3.01	Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer. ( Hirahara, N; Hyakudomi, R; Ishitobi, K; Kaji, S; Matsubara, T; Tajima, Y; Takai, K; Uchida, Y; Yamamoto, T, 2021)
"Curing locally advanced gastric cancer through surgery alone is difficult."	3.01	The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. ( Chen, H; Chen, L; Fang, X; Fu, W; He, Y; Huang, H; Ji, J; Li, F; Li, G; Li, K; Li, S; Liang, H; Liang, P; Park, S; Shen, X; Sun, Y; Suo, J; Tian, Y; Wang, X; Xin, H; Xu, Z; Xue, Y; Yang, K; Ye, Y; Zhang, Z; Zhao, Q; Zheng, Z; Zhou, Y; Zhu, L, 2021)
"Grade 3 neutropenia was common (35%)."	2.90	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019)
"Patients with potentially resectable gastric cancer were eligible."	2.90	Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. ( Chiba, Y; Imano, M; Iwama, M; Kimura, Y; Nishida, S; Shinkai, M; Shiraisi, O; Tsubaki, M; Yasuda, A; Yasuda, T, 2019)
"Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40-60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40-60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle)."	2.90	TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). ( Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S, 2019)
"The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study."	2.90	A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019)
"The incidence of oral mucositis was significantly lower in the treatment group (9."	2.90	A prospective pilot study of an elemental nutritional supplement for prevention of oral mucositis during S-1 adjuvant chemotherapy for gastric cancer. ( Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, M; Toyomasu, Y; Yanai, M; Yanoma, T, 2019)
"Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy."	2.90	Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. ( Cai, H; Du, C; Fang, Y; Huang, D; Huang, H; Jin, J; Li, G; Liu, X; Long, Z; Lu, Q; Ma, M; Sheng, W; Wang, Y; Wu, J; Xie, L; Yin, J; Zhang, Z; Zhao, G; Zhou, M; Zhou, Y; Zhu, H; Zhu, J; Zhu, X, 2019)
" However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear."	2.87	Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). ( Boku, N; Hironaka, S; Hyodo, I; Ito, M; Kimura, Y; Miura, Y; Miyata, Y; Mori, M; Moriwaki, T; Musha, N; Negoro, Y; Nishikawa, K; Nosho, K; Okuda, H; Sakamoto, T; Shinozaki, H; Shinozaki, K; Shirakawa, T; Sugimoto, N; Sukawa, Y; Takano, T; Taku, K; Tokunaga, S; Tsuda, T; Uchino, K; Yonesaka, K; Yoshimura, K; Yoshiyama, H, 2018)
" Common grade 3 or higher adverse events included neutropenia (1 in XP, 3 in SP, and 2 in SOX), decreased appetite (1 in SP), and hypertension (2 in XP)."	2.87	Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer. ( Gritli, I; Inoue, K; Kadowaki, S; Muro, K; Nishina, T; Ozeki, A; Piao, Y; Sakai, D; Shitara, K; Yoshikawa, R, 2018)
"However, the high recurrence rate makes gastric cancer difficult to cure by surgery alone."	2.82	A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, KR; Nam, TK; Park, YK; Ryu, SY; Shim, HJ, 2016)
"It was unclear whether the transhiatal approach and D2 total gastrectomy after neoadjuvant chemotherapy (NAC) for adenocarcinoma of the esophago-gastric (AEG) junction are as feasible and safe as D2 gastrectomy following NAC."	2.82	Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial. ( Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2016)
"The purpose of this phase I study of the dose escalation of oxaliplatin in combination with oral S-1 and pelvic radiation preoperatively for poor-risk lower rectal cancer was to determine the dose-limiting toxicity (DLT) and recommended dose of oxaliplatin."	2.80	A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015)
"Patients with stage II, III, or IVA esophageal cancer were randomly allocated to either 2 cycles of ICT (oxaliplatin 130 mg/m(2) on day 1 and S1 at 40 mg/m(2) twice daily on days 1-14, every 3 weeks) followed by concurrent chemoradiotherapy (CCRT) (46 Gy, 2 Gy/d with oxaliplatin 130 mg/m(2) on days 1 and 21 and S1 30 mg/m(2) twice daily, 5 days per week during radiation therapy) and esophagectomy (arm A), or the same CCRT followed by esophagectomy without ICT (arm B)."	2.80	Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer. ( Cho, KJ; Jang, G; Jung, HY; Kim, HR; Kim, JH; Kim, JY; Kim, SB; Kim, YH; Lee, GH; Ryu, JS; Song, HY; Yoon, DH, 2015)
" In both arms, S-1 dosing (oral) will be based on body surface area (80 mg/day for body surface area<1."	2.80	Randomized phase II study of S-1 dosing schedule for resected colorectal cancer. ( Doki, Y; Hasegawa, J; Hata, T; Ikeda, M; Ikenaga, M; Kato, T; Matsuda, C; Mizushima, T; Mori, M; Murata, K; Nakata, K; Nezu, R; Nishimura, J; Ohue, M; Satoh, T; Sekimoto, M; Shingai, T; Takemasa, I; Uemura, M; Yamamoto, H, 2015)
"As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone."	2.79	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). ( Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K, 2014)
"Patients with clinical stage II or III rectal cancer were treated with radiotherapy of 44 Gy in 22 fractions."	2.79	Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. ( Chen, HC; Chen, HH; Chen, WT; Chien, CR; Hsiao, CF; Lee, HH; Lin, TC; Lin, TY; Liu, TW; Wang, LW, 2014)
"In patients with highly advanced gastric cancer, the recurrence rate remains high and the prognosis disappointing."	2.79	Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-. ( Fukada, J; Fukuda, K; Kawaguchi, O; Kawakubo, H; Kitagawa, Y; Matsuda, S; Saikawa, Y; Shigematsu, N; Takahashi, T; Takeuchi, H, 2014)
" S-1 dosage was started at level 1 (55."	2.79	A phase I study of concurrent chemoradiotherapy using oral s-1 for head and neck cancer. ( Fujimoto, Y; Itoh, Y; Kato, S; Naganawa, S; Nakashima, T, 2014)
"Accuracy of the radiologic diagnosis of gastric cancer staging after neoadjuvant chemotherapy remains unclear."	2.79	Accuracy of CT staging of locally advanced gastric cancer after neoadjuvant chemotherapy: cohort evaluation within a randomized phase II study. ( Aoyama, T; Hasegawa, S; Hayashi, T; Ito, Y; Kimura, Y; Matsui, T; Miyashita, Y; Morita, S; Nishikawa, K; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2014)
"Postoperative complications were identified in 18 patients and the overall morbidity rate was 26."	2.79	Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy. ( Aoyama, T; Cho, H; Hayashi, T; Ito, Y; Miyashita, Y; Morita, S; Nishikawa, K; Ogata, T; Sakamoto, J; Tanabe, K; Tsuburaya, A; Yoshikawa, T, 2014)
" After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2."	2.79	Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014)
"The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy."	2.79	Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. ( Buyse, M; Fukushima, R; Hara, A; Imamura, H; Kobayashi, M; Kojima, H; Miyashita, Y; Morita, S; Nishikawa, K; Nozaki, I; Oba, K; Sakamoto, J; Takahashi, M; Takahashi, N; Takiguchi, N; Tanabe, K; Tatsumoto, N; Tsuburaya, A; Yoshida, K; Yoshino, S, 2014)
"4%) and renal adverse events (all grades: CS, 18."	2.78	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013)
"Adjuvant chemotherapy trial of TS-1 for gastric cancer study demonstrated that postoperative S-1 chemotherapy for 1 year improved overall survival of locally advanced gastric cancer (LAGC) patients."	2.78	A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( Choi, YH; Jung, HY; Kang, HJ; Kang, YK; Kim, BS; Kim, HJ; Kim, KC; Lee, GH; Park, I; Park, YS; Ryu, MH; Yook, JH, 2013)
" The dosage of S-1 was based on the body surface area (BSA) as follows: 40 mg bid (total 80 mg/day) for a BSA of <1."	2.78	Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. ( Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY, 2013)
" In the present study we estimated radiation dose-response curves for various grades of tumor regression after preoperative CRT."	2.78	Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. ( Appelt, AL; Bentzen, SM; Jakobsen, A; Pløen, J; Vogelius, IR, 2013)
"Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases."	2.78	Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013)
"S-1 in patients with advanced gastric cancer (AGC)."	2.78	Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. ( Lu, XY; Wang, ML; Wang, X; Yang, JF; Yu, HG; Zhou, LY, 2013)
" However, because of decreased relative dose intensity during treatment, further study is warranted to determine optimal dosage and combination."	2.77	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. ( Ahn, JY; Chung, HC; Hyung, WJ; Jeung, HC; Lee, SS; Noh, SH; Rha, SY, 2012)
"We investigated stage IV gastric cancer patients who underwent surgery with curative intent after S-1-based chemotherapy between 2000 and 2008."	2.77	Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study. ( Ajioka, Y; Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Yajima, K, 2012)
"The aim of this study was to evaluate the safety and efficacy of vaccination with human leukocyte antigen (HLA)-A24-restricted human vascular endothelial growth factor receptor 1 (VEGFR1)-1084 and VEGFR2-169 combined with chemotherapy in patients with advanced gastric cancer."	2.77	Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. ( Doki, Y; Fujiwara, Y; Kurokawa, Y; Masuzawa, T; Miyata, H; Mori, M; Nakajima, K; Nakamura, A; Nakamura, Y; Okada, K; Osawa, R; Takeda, K; Takiguchi, S; Tsunoda, T; Yamasaki, M; Yoshida, K, 2012)
"To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma."	2.77	[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012)
"Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy."	2.76	A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. ( Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K, 2011)
"Gemcitabine 1250 mg/m² was administered on the 1st and 8th days of the cycle, tegafur 750 mg/m²/day for 21 consecutive days and LV 25 mg/day continuously, every 28 days, with a maximum of six cycles."	2.76	Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. ( Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E, 2011)
" Pharmacokinetic analysis of S-1 was performed at cycle 1."	2.76	Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. ( Bae, KS; Chang, HM; Hong, YS; Jang, G; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, SS; Lim, HS; Ryu, MH; Shin, JG, 2011)
"Eighteen patients with advanced gastric cancer in addition to confirmed peritoneal metastasis using laparoscopy were enrolled in this study."	2.76	Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study. ( Higashijima, J; Iwata, T; Kurita, N; Miyatani, T; Morimoto, S; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K, 2011)
" We investigated the activity and toxicity of S-1 in combination with cisplatin in patients with unresectable non-small cell lung cancer (NSCLC)."	2.76	An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. ( Baggstrom, M; Graham, C; Herbst, R; Jones, D; Saito, K; Sandler, A; Zergebel, C, 2011)
"Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks."	2.76	Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011)
" Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity."	2.76	[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011)
" paclitaxel (PTX) combined with S-1 was carried out in gastric cancer patients with peritoneal metastasis."	2.75	Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2010)
"In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU), tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after administration of S-1 at 35 or 40 mg/m(2) bid for 28 consecutive days, in Cycles 1 and 3, in patients with advanced gastric cancer."	2.75	Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. ( Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2010)
"This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients."	2.75	Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer. ( Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S, 2010)
"CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy."	2.75	Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. ( Ito, S; Kodera, Y; Kojima, T; Mochizuki, Y; Nakanishi, H; Yamamura, Y, 2010)
"Clinically serosa-positive (T3-4) gastric cancer has a poor prognosis."	2.75	A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). ( Fujii, M; Kobayashi, O; Nakajima, T; Nashimoto, A; Omura, K; Takabayashi, A; Yamada, T; Yamaguchi, T; Yamaue, H; Yoshikawa, T, 2010)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."	2.74	Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
" A pharmacokinetic study of PTX was also performed."	2.74	Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. ( Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H, 2009)
"This cycle was continued until disease progression or intolerable adverse events."	2.74	A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). ( Fujiwara, M; Ito, S; Kodera, Y; Kojima, H; Kojima, T; Kondo, K; Koshikawa, K; Matsui, T; Mochizuki, Y; Nakao, A; Suzuki, N; Takase, T; Tsuboi, K, 2009)
"Patients with metastatic or recurrent gastric cancer, no prior chemotherapy, measurable disease, ECOG performance status less than 3 and adequate organ functions were eligible for the study."	2.74	Phase I study of the sequential administration of S-1 and cisplatin for metastatic gastric cancer. ( Ariyama, H; Baba, E; Esaki, T; Fujishima, H; Harada, M; Kato, K; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Tanaka, R, 2009)
"Patients with advanced or metastatic colorectal cancer (CRC) received: UFT 300 mg/m(2), LV 75 mg/body and CPT-11 150 mg/m(2) (UFT and LV given on days 1-14, and CPT-11 on day 1, every 3 weeks)."	2.74	A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. ( Fukunaga, M; Furukawa, H; Ishida, H; Kato, T; Miyake, Y; Takemoto, H; Watanabe, Y, 2009)
"This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer."	2.74	Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. ( Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I, 2009)
"Paclitaxel was administered intravenously on days 1, 8 and 15, at an initial dose of 40 mg/m(2), stepping up to 70 mg/m(2) in 10-mg/m(2) increment."	2.74	Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. ( Fukunari, H; Hatano, T; Hayashi, T; Inada, S; Kawauchi, Y; Nikkuni, K; Nishimura, A; Sato, T; Shimizu, T; Sugita, M; Takahashi, S; Tomidokoro, T; Yanagi, M; Yoshida, H, 2009)
"More than two-thirds of patients with gastric cancer present with metastatic disease and their curative options are limited."	2.73	Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer. ( Baruch, NB; Biran, H; Dinerman, M; Idelevich, E; Karminsky, N; Katsenelson, RL; Man, S; Shani, A; Zvi, NB, 2007)
" A pharmacokinetic study was performed on day 28 of cycles 1 and 3."	2.73	Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. ( Ahn, JB; Chung, HC; Gong, SJ; Jeung, HC; Kim, HK; Kim, S; Kim, SY; Lim, HY; Noh, SH; Park, CH; Rha, SY, 2007)
"Systemic chemotherapy for gastric cancer is often associated with treatment-related toxicity, which is particularly severe in patients with a poor performance status."	2.73	A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. ( Ahn, JB; Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ, 2007)
"Twenty-two patients with metastatic colorectal cancer were enrolled in the phase I trial and 35 patients (including eight patients treated at level 4 during phase I) were evaluated in the phase II trial."	2.73	Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. ( Fukunaga, M; Furukawa, H; Gotoh, M; Ishida, H; Ishihara, R; Narahara, H; Okamura, S; Takiuchi, H; Tomita, N; Uedo, N, 2007)
"Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined."	2.73	A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. ( Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, HG; Kim, JH; Kim, SW; Kim, TY; Kim, YJ; Lee, KW; Lee, SH; Oh, DY; Oh, SY; Yoon, YB, 2008)
"Although the prognosis in patients with pancreatic cancer has been poor, we recently reported unusually high response rate and survival benefit of S-1 treatment in patients with pancreatic cancer."	2.73	High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008)
"S-1 plus cisplatin is active against gastric cancer and has a favorable toxicity profile."	2.72	Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. ( Ajani, JA; Benson, AB; Haller, DG; Lee, FC; Lenz, HJ; Phan, AT; Singh, DA; Strumberg, D; Yanagihara, R; Yao, JC, 2006)
"He died of brain metastases."	2.72	[A case of adenocarcinoma of the lung significantly responding to TS-1 plus cisplatin combination chemotherapy]. ( Asou, H; Ichinose, Y; Maruyama, R; Okamoto, T; Suemitsu, R; Wataya, H, 2006)
"Lentinan (LNT) is a beta-glucan known to have a life-prolonging effect in combination with chemotherapy for patients with unresectable or recurrent gastric cancer."	2.72	[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. ( Kashimura, H; Kashiwagi, H; Mitsumori, N; Nimura, H; Takahashi, N; Takayama, S; Yanaga, K, 2006)
"The incidence and mortality of pancreatic cancer has increased very rapidly in Japan."	2.72	[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. ( Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006)
"We treated 12 patients with advanced gastric cancer with 80 mg/m2 of S-1 for 21 days and 60 mg/m2 of cisplatin (CDDP) on day 8 every 5 weeks."	2.71	Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2003)
" Therefore, we conducted a phase II study of gemcitabine combined with UFT in metastatic pancreatic cancer patients and assessed the efficacy and the toxicity of the regimen."	2.71	Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY, 2004)
"In resectable rectal cancer, if preoperative treatment is considered, this approach can be an option."	2.71	Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up. ( Almenar, D; Aparicio, J; Arlandis, F; Bosch, C; Campos, J; Campos, JM; Climent, MA; Estevan, R; Fernández-Martos, C; Garcera, S; Hernandez, A; Maestu, I; Mengual, JL; Puchades, R; Richart, JM; Tormo, A; Torregrosa, M; Uribe, N; Vicent, JM; Viciano, V, 2004)
"Our aim was to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and recommended dose of oxaliplatin combined with oral tegafur-uracil and leucovorin."	2.71	Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. ( Chen, JS; Huang, JS; Liau, CT; Lin, YC; Rau, KM; Wang, HM; Yang, TS, 2005)
"Ten patients with resectable esophageal cancer were enrolled."	2.71	Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer. ( Beauchamp, RD; Berlin, J; Blanke, CD; Caillouette, C; Chakravarthy, B; Choy, H; Leach, S; Roberts, J; Shyr, Y; Tarpley, J; Tedesco, KL; Teng, M; Wyman, K, 2005)
"Uracil-tegafur (UFT) has been reported to have broad antitumor activity in a variety of malignancies."	2.71	A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Okusaka, T; Ueno, H, 2005)
" Therefore, we initiated a phase I pharmacokinetic study of this combination in our gastric cancer patients."	2.71	Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. ( Ajani, JA; Anbe, H; Carr, KL; Faust, J; Houghton, M; Ikeda, K; Urrea, P; Yao, JC, 2005)
"Uracil-tegafur (UFT) has been reported to have a broad anti-tumor activity in a variety of malignancies including colorectal cancer and breast cancer."	2.70	Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002)
"To evaluate the efficacy of chemoendocrine therapy for the initial treatment of stage D2 prostate cancer, we conducted a prospective randomized study which compared combined androgen blockade alone to that combined with UFT."	2.69	[Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT]. ( Akazawa, S; Aki, M; Hashine, K; Kuwahara, M; Sumiyoshi, Y; Takenaka, A; Yamamoto, A, 1999)
"Of the 136 patients with prostate cancer enrolled in this study from April 1990 to December 1992, 69 received endocrine plus UFT therapy and the remaining 67 received endocrine-only therapy."	2.69	Endocrine plus uracil/tegafur therapy for prostate cancer. ( Kawada, Y; Kuriyama, M; Ohshima, S; Ono, Y; Shimizu, H; Takahashi, Y, 1999)
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."	2.69	A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000)
" The Kaplan-Meier overall and cancer specific survival analysis estimates that the chronic administration of antimetabolites did not improve the cumulative 5-year survival in the SCC group."	2.68	[Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer]. ( Hirota, Y; Hongo, J; Iijima, Y; Inagaki, M; Koyama, M; Ozaki, M; Wada, K, 1995)
"We evaluated the usefulness of hormonal therapy combined with UFT as initial treatment in comparison with hormonal therapy alone in 92 patients with Stage D2 prostatic cancer treated at the Department of Urology, Dokkyo University School of Medicine between 1974 and 1993."	2.68	[Clinical evaluation of chemohormonal therapy as an initial treatment for stage D2 prostatic cancer--effect of UFT administration combined with hormonal therapy]. ( Chen, JA; Honda, M; Hosoya, Y; Imai, T; Maeda, S; Suzuki, T; Takasaki, E, 1995)
"Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period."	2.68	[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995)
" Trials of new combinations are warranted to take advantage of the pharmacokinetic properties and oral bioavailability of UFT and leucovorin."	2.68	Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P, 1997)
"UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer."	2.68	UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas. ( Mani, S, 1997)
"Thirty-four patients with advanced gastric cancer were treated with combination chemotherapy employing Tegafur-Uracil (UFT), etoposide, Adriamycin, and Cisplatinum (CDDP) (UFT-EAP therapy)."	2.67	Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer. ( Chin, K; Hattori, T; Hayakawa, M; Maeda, H; Morise, K; Morooka, Y; Saito, H; Sugihara, M, 1994)
"We studied the usefulness and safety of long-term administration of uracil and tegafur (UFT) after primary therapy of the malignant tumor in jaw and oral cavity regions randomized controlled trial."	2.67	[Multiple cooperative study of UFT-adjuvant chemotherapy for malignant tumor in the jaw and oral cavities. The Oral Surgery Malignant Tumor Research Association in Kanto Kohshinetsu District]. ( Asakura, A; Fukuda, H; Hagiwara, T; Kobayashi, A; Kotani, A; Nemoto, K; Sakamoto, H; Sunada, O; Takaku, S; Tamura, M, 1994)
" No severe side effects appeared in either of the groups, and a long-term administration was safe."	2.67	[Multihospital co-operative study of post-operative adjuvant chemotherapy in the treatment of gastric cancer-(Part 3). Comparisons between tegafur and UFT. North Kyushu Co-operative Study Group for Cancer Chemotherapy]. ( Abe, R; Arima, S; Fukuyama, N; Hisatsugu, T; Nakamura, Y; Ohkuma, R; Ohsato, K; Taira, A; Yamamoto, H; Yamanouchi, A, 1991)
"Apatinib has been proven to significantly prolong the survival of the patients with advanced chemotherapy-refractory gastric cancer."	2.66	S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. ( Liu, D; Yu, GM; Zhang, C; Zhang, M, 2020)
"Twenty-seven pts with squamous cell carcinoma were randomized between regimen PMP (CDDP 60 mg/m2, d 1, MMC 6 mg/m2, d 3, d 10 and PEP 5 mg/m2, d 3-7) and regimen PM (CDDP 60 mg/m2, d 1 and MMC 6 mg/m2, d 3, d 10)."	2.66	[A randomized trial with various combinations of cis-platinum (CDDP), mitomycin C (MMC), peplomycin (PEP) and ftorafur (FT) in the treatment of non-small cell lung cancer]. ( Abe, S; Miyamoto, H; Nakabayashi, T; Ohosaki, Y; Yasuda, S, 1986)
"140 patients with advanced gastric cancer confirmed by pathology were treated by UFT (Uracil, FT-207) and mitomycin C (MMC) from Sept."	2.66	[Combined UFTM for 140 patients with advanced gastric cancer]. ( Jin, ML, 1989)
" The maximum dosage of CDDP administered was gradually increased step by step from 20 mg/day to 40 mg/day every week."	2.66	[A clinical trial of cis-platinum (II) in combination with PSK and FT-207 in advanced stomach cancer]. ( Atarashi, J; Fukuo, Y; Hayashi, Y; Terashi, A; Yano, Y, 1985)
"positive cases in gastric cancer (4/40)."	2.65	[Sex hormone dependency and endocrine therapy in diffuse carcinoma of the stomach]. ( Kitaoka, H, 1983)
"In metastatic gastric cancer, the addition of ramucirumab, an antivascular endothelial growth factor receptor 2-targeted antibody, to first-line chemotherapy did not improve survival over chemotherapy alone."	2.58	Advances in the treatment of gastric cancer. ( Ilson, DH, 2018)
"However, recurrence occurred and the patient achieved complete response following tegafur/gimeracil/oteracil-based chemotherapy."	2.55	Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature. ( Ikeyama, M; Ishizone, S; Nakayama, J; Yoshizawa, J, 2017)
"The patient is alive and well without recurrence for more than 10years after lung resection."	2.55	[A Case of Recurrent Rectal Cancer with Adrenal and Lung Metastasis with More than Ten-Year Survival after Surgery]. ( Fuse, T; Katarao, Y; Kimura, Y; Shimizu, Y; Takemura, M; Tanaka, R; Uchiyama, K; Yamamoto, Y, 2017)
"An 80-year-old man with type 4 gastric cancer in the mid-gastric region underwent total gastrectomy and D2-No."	2.52	[Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination]. ( Ito, M; Kitano, M; Kunishige, T; Matsumoto, S; Migita, K; Nakade, H; Nakajima, Y; Nakatani, M; Tanaka, T; Wakatsuki, K, 2015)
"This is a case report of gastric cancer with a tumor embolus in the portal vein of a 76-year-old male."	2.50	[A case report of distal gastrectomy with thrombectomy after NAC for Gastric cancer]. ( Fujino, M; Inaba, S; Ito, N; Kitai, S; Mochizuki, S; Nagata, T; Nakase, Y; Yamazato, Y, 2014)
"Gastric cancer is the fourth most common malignancy worldwide with Japan, Korea, Taiwan, China, Mongolia and many countries in South America and eastern Europe, as well as parts of the Middle East, contributing to the majority of cases."	2.47	A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. ( Ajani, JA; Blum, M; Suzuki, A, 2011)
"Without any sign of infection, leukocytosis developed around the 30th POD."	2.46	Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. ( Asada, Y; Fujisawa, K; Iida, Y; Kawaguchi, M; Mitsui, T; Miura, S; Munemoto, Y; Sudo, Y; Takehara, A; Terada, T, 2010)
"Although there are many randomized clinical trials of late course accelerated hyperfractionated radiotherapy (LCAHFR) combined with FP chemotherapy for esophageal cancer, the efficacy and toxicity are controversial."	2.46	Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. ( Gao, XS; Li, XY; Liu, CX, 2010)
"Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months."	2.44	Chemotherapy of advanced gastric cancer. ( López-Brea, MF; Rivera, F; Vega-Villegas, ME, 2007)
" Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6."	2.44	Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007)
"Case 1 of type 3 advanced gastric cancer underwent surgery after one week interval following oral administration of TS-1 at a daily dose of 80 mg/body for 2 weeks."	2.43	[Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1]. ( Koizumi, H; Nakamura, K; Nakane, Y; Nakano, K; Okugawa, K; Osaka, Y; Sako, H; Tanabe, S; Tsuchiya, K, 2005)
"FT suppository for rectal cancer is considered to be safe and effective."	2.40	[Moderately differentiated adenocarcinoma of the rectum: a case report of remarkable response to preoperative administration of FT suppository]. ( Anzai, T; Izumi, M; Kawate, S; Morishita, Y; Ohwada, S; Sasaki, A; Tokizawa, N, 1997)
"To study the effect of tegafur administration combined with hormonal therapy on the survival rate of newly diagnosed patients with stage D prostatic cancer, 66 patients, 70."	2.38	[Effect of tegafur administration combined with hormonal therapy in patients with newly diagnosed stage D prostatic cancer]. ( Horiuchi, S; Kobayashi, N; Kojima, S; Negishi, T; Saitoh, H; Satake, I; Takahashi, T; Tari, K; Tsujii, T; Yoshida, K, 1990)
" The use of camrelizumab did not increase postoperative complications or the adverse effects of neoadjuvant therapy."	1.62	Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion. ( Chen, QY; Huang, CM; Li, P; Lin, JL; Lin, JP; Lin, JX; Lu, J; Wang, JB; Xie, JW; Zheng, CH, 2021)
"Watchful waiting in patients with rectal cancer with complete clinical response after chemoradiation therapy has gained increased popularity to avoid morbidity and mortality associated with surgery."	1.56	Abnormal Neuronal Response to Rectal and Anal Stimuli in Patients Treated for Distal Rectal Cancer With High-Dose Chemoradiotherapy Followed By Watchful Waiting. ( Brock, C; Christensen, P; Gram, M; Haas, S; Krogh, K; Laurberg, S; Lundby, L; Mohr Drewes, A; Møller Faaborg, P, 2020)
"To study the prognostic factors of gastric cancer (GC) patients who were classified with stage III disease according to the newest TNM classification."	1.51	Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification. ( Li, L; Pan, C; Wang, Y; Wei, J; Yao, T; Zhang, N, 2019)
" Adverse events related to S-1 treatment were mostly grade 1 or 2 while reported grade 3-4 serious adverse events related to S-1 occurred in 12 patients and were most often grade 3 neutropenia (n = 4, 3."	1.51	S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. ( Venerito, M, 2019)
"Adjuvant chemotherapy for gastric cancer, particularly stage III, improves survival after curative D2 gastrectomy."	1.51	Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ, 2019)
"All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively."	1.48	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018)
"Dissemination of gastric cancer tends to be difficult to treat and has a poor prognosis."	1.48	[Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma]. ( Ajioka, Y; Alexey, A; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A, 2018)
" The patient received gamma knife stereotactic radiosurgery (GKSRS) combined with S-1 treatment."	1.46	Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report. ( Dong, X; Du, F; Tang, S; Wei, H; Wei, J, 2017)
"Although the prognosis of gastric cancer with synchronous liver metastases is very poor, it is possible for survival to be prolonged with multimodality therapy."	1.46	[A Case of Advanced Gastric Cancer with Synchronous Liver Metastases Responding to Preoperative Combination Chemotherapy with S-1 plus Oxaliplatin(SOX)]. ( Ebisui, C; Fukuchi, N; Hamano, R; Kinuta, M; Kitahara, T; Minoji, T; Murata, K; Ohishi, K; Okamura, S; Yanagisawa, T; Yokouchi, H, 2017)
"Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed."	1.46	Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017)
"A total of 198 patients with rectal cancer underwent preoperative endoscopic assessments after chemoradiotherapy."	1.46	Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer. ( Fukayama, M; Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Watanabe, T, 2017)
"There was no recurrence for more than 2 years after the lung surgery."	1.46	[A Recurrent Case of Thymic Adenocarcinoma Effectively Treated with S-1 Over a Long-Term Period]. ( Ikeda, H; Kakegawa, S; Matsumoto, I; Saito, D; Takata, M; Takemura, H; Tamura, M; Tanaka, Y; Yoshida, S, 2017)
"Advanced sigmoid colon cancer with stenosis was discovered in a man in his 50's who presented with constipation."	1.43	[Pathological Complete Response to SOX plus Bevacizumab for Treating Stage IV Sigmoid Colon Cancer]. ( Emi, M; Hirabayashi, N; Ibuki, Y; Kagimoto, A; Kaneko, M; Mukaida, H; Takiyama, W; Yoshimitsu, M, 2016)
"Although gastric cancer with main portal vein tumor thrombus is a rare occurrence, its prognosis is extremely poor."	1.43	A long-surviving case of gastric cancer with main portal vein tumor thrombus after surgical resection and postoperative S-1 therapy. ( Kanemoto, H; Kyoden, Y; Nagai, E; Oba, N; Ohata, K; Sato, S; Suzuki, M; Takagi, M; Takahashi, M; Taki, Y; Taku, K; Watanabe, M, 2016)
"We made a diagnosis of pancreatic cancer, and the patient underwent pancreaticoduodenectomy."	1.43	[A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. ( Aoyama, T; Atsumi, Y; Kazama, K; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Rino, Y; Shiozawa, M; Ueno, M; Washimi, K; Yukawa, N, 2016)
"The standard of care for stage II/III gastric cancer in Japan is D2 dissection followed by adjuvant S-1 monotherapy."	1.42	A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106). ( Ishigure, K; Ishiyama, A; Ito, S; Kobayashi, D; Kodera, Y; Kurimoto, K; Matsui, T; Mochizuki, Y; Nakao, A; Nakayama, H; Sakamoto, J; Tanaka, N, 2015)
"Primary stromal cells isolated from gastric cancer tissue (GCSC) and normal gastric tissue (Gastric stromal cell: GSC) in each patient were cultured and subjected to comprehensive proteome (LC-MS/MS) and real-time RT-PCR analysis."	1.42	Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer. ( Fukui, H; Hirota, S; Kaibe, N; Kikuchi, S; Maeyama, Y; Matsumoto, M; Miwa, H; Morimoto, K; Nakamori, S; Niwa, H; Sasako, M; Takemura, M, 2015)
"Patients with esophageal cancer treated with esophagectomy by the same surgeon between 2004 and 2011 were reviewed."	1.42	Preoperative chemoradiation therapy decreases the number of lymph nodes resected during esophagectomy. ( Batirel, HF; Bilgi, Z; Celikel, CA; Ermerak, NO; Issaka, A; Kara, VH, 2015)
"AFP-producing gastric cancer with a PVTT has an extremely poor prognosis, but long-term survival was achieved for this dismal condition by salvage surgery after chemotherapy."	1.42	Salvage surgery after chemotherapy with S-1 plus cisplatin for α-fetoprotein-producing gastric cancer with a portal vein tumor thrombus: a case report. ( Hirakawa, K; Hori, T; Inaba, M; Ishikawa, T; Kuroda, K; Nakao, S; Nakata, B; Tendo, M, 2015)
"The prognosis of unresectable gastric cancer is poor."	1.42	Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. ( Fukuchi, M; Ishibashi, K; Ishida, H; Ishiguro, T; Kumagai, Y; Kuwano, H; Mochiki, E; Ogata, K; Suzuki, O, 2015)
"5-Fluorouracil-based chemotherapy is considered to be a radiosensitizer; however, conventional short-course radiotherapy combined with chemotherapy is generally thought to not be feasible because of the prevalence of side effects."	1.42	Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer. ( Beppu, N; Doi, H; Kakuno, A; Kamikonya, N; Matsubara, N; Tomita, N; Yamanaka, N; Yanagi, H, 2015)
"Clinical reports of 190 gastric cancer patients treated with S-1 chemotherapy, with or without PSK, at Kochi Medical School between 2007 and 2012 were investigated retrospectively to analyze survival."	1.42	Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1). ( Fukudome, I; Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Munekage, M; Namikawa, T; Ogawa, M; Shiga, M, 2015)
"Recent advances in gastric cancer chemotherapy have made macroscopic complete resection possible in some patients with stage IV disease."	1.42	Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. ( Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Tajima, H; Takamura, H; Tsukada, T, 2015)
"A 64-year-old man was diagnosed with pancreatic cancer by abdominal computed tomography (CT)."	1.42	[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy]. ( Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K, 2015)
"The pulmonary metastases of gastric cancer often develop along with carcinomatous lymphangiosis or carcinomatous pleurisy, and isolated pulmonary metastasis is rare."	1.42	[A Case of Surgical Resection of Isolated Pulmonary Metastasis from Gastric Cancer]. ( Goto, H; Hirano, T; Hoshino, M; Imaizumi, K; Kakimoto, M; Koshiishi, H; Matsuyama, T; Murata, T; Nakata, T; Okuno, K; Tokura, M; Yoshimura, T, 2015)
"Peritoneal metastasis of breast cancer was suspected, and an operation was performed for a definitive diagnosis."	1.42	[A Case of Peritoneal Metastasis of Breast Cancer Diagnosed by Laparoscopic-Assisted Right Hemicolectomy]. ( Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kusama, H; Matsushita, K; Morimoto, Y; Motoyama, Y; Murakami, K; Nagano, T; Naito, A; Nakatsuka, S; Nitta, K; Ohmura, Y; Ohneda, Y; Okishiro, M; Sakisaka, H; Sato, Y; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H, 2015)
"We report a long surviving case of gastric cancer with a synchronous adrenal metastasis in a patient who underwent curative resection."	1.42	[A Long Surviving Case of Resected Advanced Gastric Cancer with a Synchronous Adrenal Metastasis]. ( Endo, S; Fujitani, K; Fushimi, H; Hama, N; Haraguchi, N; Hirao, M; Ikeda, M; Kawada, J; Maeda, S; Miyake, M; Miyamoto, A; Nakamori, S; Nishikawa, K; Sekimoto, M; Yamamoto, K, 2015)
"Abdominal computed tomography showed gastric cancer invasion to the left liver lobe."	1.42	[A Case of Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy]. ( Kawamoto, S; Maeno, H; Munechika, T; Nagao, S; Nomi, M; Okamoto, T; Sasaguri, T; Sueishi, K; Tanaka, K; Yonemitsu, K, 2015)
"Here, we report a case of advanced gastric cancer that demonstrated CR after treatment with S-1 and paclitaxel."	1.42	[A Case Report of Advanced Gastric Cancer Demonstrating CR after Treatment with S-1 and Paclitaxel]. ( Koga, Y; Kudoh, K; Ogata, K; Ohchi, T; Ootao, R, 2015)
"She was diagnosed with rectal cancer via colonoscopy."	1.42	[A Case of Locally Advanced Rectal Cancer with a Pathological Complete Response to Preoperative Chemoradiotherapy]. ( Akahoshi, S; Iizaka, M; Murakami, S; Nimura, S; Takeguchi, T, 2015)
"A 58-year-old woman with advanced gastric cancer underwent total gastrectomy in May 2012."	1.42	Complete Response Obtained with S-1 Plus CDDP Therapy in a Patient with Multiple Liver Metastases from Gastric Cancer. ( Inagaki, M; Iwagaki, H; Nonoshita, T; Otsuka, S, 2015)
"Fifty-two patients with pancreatic cancer who underwent surgical resection were enrolled in this study."	1.40	Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. ( Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2014)
"The optimal radiotherapy technique and combination with systemic therapy in locally advanced gastric cancer patients are far from being resolved despite the fact that radiochemotherapy is becoming more attractive in contemporary clinical practice."	1.40	Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients. ( Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014)
"Here we report a case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy."	1.40	[A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy]. ( Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y, 2014)
"Gemcitabine plus S-1 was again administered as postoperative adjuvant chemotherapy."	1.40	Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case. ( Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T, 2014)
"The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009."	1.40	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014)
"The standard treatment for stage IV gastric cancer is chemotherapy, but outcomes remain poor."	1.40	Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients. ( Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O, 2014)
"Six months after surgery, recurrence was detected in the para-aortic lymph node."	1.40	[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N, 2014)
"A 55-year-old man suffering from gastric cancer associated with metastases to the lymph node, gallbladder, and liver was administered chemotherapy with S-1 and cisplatin."	1.40	[A case of metastatic colon carcinoma following curative resection for advanced gastric cancer associated with metastases to the liver and gallbladder]. ( Akiyama, Y; Hasuike, Y; Higuchi, I; Miyamoto, M; Tanigawa, T; Yamamoto, M, 2014)
"However, the Krukenberg tumor rapidly increased in size after 4 years and she complained of abdominal distension."	1.40	Giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case. ( Harada, T; Isogai, M; Kamei, K; Kaneoka, Y; Maeda, A; Sunagawa, M; Takayama, Y, 2014)
"The trastuzumab for Gastric Cancer study newly defined tumors that were positive for human epidermal receptor-2 (Her-2) and created a Her-2-oriented treatment strategy that is also applicable in the adjuvant setting for stage 2/3 cancers."	1.39	Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. ( Aoyama, T; Cho, H; Hayashi, T; Kameda, Y; Masuda, M; Miyagi, Y; Oshima, T; Rino, Y; Shirai, J; Tsuburaya, A; Yoshikawa, T; Yukawa, N, 2013)
"Choroidal or cutaneous metastasis of gastric cancer is rare."	1.39	Choroidal and cutaneous metastasis from gastric adenocarcinoma. ( Ezaki, H; Hayashi, Y; Iijima, H; Kawai, S; Miyazaki, M; Nakai, K; Nishida, K; Nishida, T; Shinzaki, S; Takehara, T; Tsujii, M; Watabe, K; Yakushijin, T; Yamada, T, 2013)
"Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups."	1.39	Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. ( Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X, 2013)
"Pancreatic cancer is frequently complicated by malignancies in other organs."	1.39	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. ( Gabata, T; Ikeda, H; Ishikawa, D; Iwakami, S; Matsui, O; Mouri, H; Nanjo, S; Ohtsubo, K; Takamatsu, Y; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K, 2013)
"Patients who had Japanese Gastric Cancer Association (JGCA) cStage IIIB gastric cancer were enrolled onto this study and received oral S-1 (65 mg/m(2)/day) administration and 50-Gy radiotherapy followed by radical surgery."	1.38	Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. ( Hagiike, M; Inoue, T; Kimura, T; Okano, K; Suzuki, Y; Usuki, H; Yachida, S, 2012)
"Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck."	1.38	Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012)
" The types and incidence rate of adverse events related to chemotherapy and the results of follow up of the patients were analyzed."	1.38	[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer]. ( Chi, Y; Huang, J; Lü, X; Qu, T; Wang, JW; Yang, L; Zhou, Y, 2012)
"Chemo-naïve patients with unresectable pancreatic cancer were enrolled."	1.37	Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. ( Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T, 2011)
"In patients with stage II/III gastric cancer, tumors often recur even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy."	1.37	Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. ( Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T, 2011)
"Although the prognosis of gastric cancer with carcinomatous lymphangitis is poor."	1.37	[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with carcinomatous lymphangitis of the lung]. ( Daimon, Y; Kito, F; Mochizuki, Y; Takahashi, M; Watanabe, J; Yabuno, T; Yoshida, S, 2011)
"To observe the local control rate, survival time and side effect of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma."	1.37	[Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma]. ( Li, WL; Liu, XH, 2011)
" To the best of our knowledge, cases of EGC combined with metachronous osteosclerotic multiple bone and bone marrow metastases that respond to chemoradiotherapy are very rare."	1.37	Early gastric cancer combined with multiple metachronous osteosclerotic bone and bone marrow metastases that responded to chemoradiotherapy. ( Chiba, F; Kiyozaki, H; Konishi, F; Saito, M; Shuto, C; Takata, O; Yamada, S; Yoshida, T, 2011)
"No distant recurrence was noted during this time."	1.37	[A case of breast cancer with postoperative metastasis to the supraclavicular lymph nodes-recurrence-free survival achieved by surgical excision following chemotherapy]. ( Dan, N; Hori, T; Nishino, H; Tendo, M; Tezuka, K, 2011)
"She was diagnosed as a type 3 gastric cancer (por/tub2) of the esophagogastric junction by gastrointestinal endoscopy in November 2010."	1.37	[A case of adenocarcinoma of the esophagogastric junction successfully treated with chemoradiation therapy]. ( Ebisui, C; Ide, Y; Kinuta, M; Momozane, T; Mukai, R; Murakami, M; Murata, K; Nagase, H; Nishigaki, T; Okada, K; Owada, Y; Tamai, M; Yanagisawa, T; Yokouchi, H, 2011)
"We present here a 23-year-old gastric cancer patient who first presented with right-side testis swelling and pain."	1.36	The unusual presentation of gastric adenocarcinoma as a testicular mass: a favorable response to docetaxel and Cisplatin plus oral tegafur/uracil and leucovorin. ( Chao, Y; Kuo, JY; Lee, RC; Li, AF; Li, CP; Luo, JC; Yang, KC, 2010)
"HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased stage of tumor between the groups."	1.36	Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone. ( Matsui, N; Nakao, K; Tsunoda, A; Tsunoda, Y; Watanabe, M, 2010)
"Paclitaxel was administered at 120 mg/m(2) on day 1 and S-1 was administered orally at 80 mg/m(2) for 14 consecutive days, followed by a 1-week rest, as one course."	1.36	Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer. ( Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Uji, K; Yoshida, A, 2010)
" The regimen of pre-op CCRT was a radiation dosage of 45 Gy in 20 fractions and oral tegafur-uracil (UFUR) and leucovorin."	1.36	The impact of preoperative chemoradiotherapy on advanced low rectal cancer. ( Chang, SC; Chen, WS; Jiang, JK; Kao, PS; Lee, RC; Liang, WY; Lin, JK; Lin, TC; Wang, HS; Wang, LW; Yang, SH, 2010)
" Therefore, we reduced the administration dosage to 60 mg/ day."	1.36	[An elderly patient with advanced gastric cancer maintaining complete response for over 3 years by oral administration of UFT following short span of S-1]. ( Baba, H; Beppu, T; Okabe, K; Sano, O; Sugiyama, S; Wada, A; Yamanaka, T, 2010)
"The prognosis of type 4 advanced gastric cancer is extremely poor, even the use of multidisciplinary treatment cannot provide satisfactory results."	1.36	[Preoperative S-1/CDDP combination chemotherapy was effective in a case of local advanced gastric cancer]. ( Hamada, H; Hayashi, S; Katsuki, Y; Kina, M; Kuraya, D; Takada, J; Watanabe, K, 2010)
"A 77-year-old man had sigmoidectomy for sigmoid colon cancer."	1.36	[Adrenalectomy for solitary adrenal metastasis from colorectal cancer]. ( Akaike, M; Mikayama, Y; Morinaga, S; Shiozawa, M; Tamagawa, H; Tamura, S; Watanabe, T; Yamamoto, N, 2010)
"Gemcitabine was administered once a week for 3 weeks followed by a week rest."	1.36	[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy]. ( Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T, 2010)
"In 2009, lung cancer was found."	1.36	[A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy]. ( Chika, N; Dan, N; Goto, H; Hosokawa, T; Kakimoto, M; Kato, H; Koshiishi, H; Masuda, T; Matsuyama, T; Mitsuhashi, Y; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H; Yoshimura, T, 2010)
"Analysis of 50 consecutive resected gastric cancer patients who received adjuvant chemotherapy with Tegafur for polymorphisms of genes DPYD1 (A/G; Ile543Val), DPYD2 (C/T; Arg29Cys) and CDA (A/C; Lys27Gin)."	1.35	Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. ( Bombí, JA; Caballero, M; Campayo, M; Conill, C; Domingo-Domenech, J; Grau, JJ; Monzó, M; Muñoz-García, C; Navarro, A, 2008)
"We herein describe the case of a patient with advanced gastric carcinoma combined with extra-adrenal pheochromocytoma who received a radical operation after undergoing neoadjuvant chemotherapy."	1.35	Advanced gastric carcinoma combined with extra-adrenal pheochromocytoma resected after three courses of S-1 and cisplatin as neoadjuvant chemotherapy: report of a case. ( Inamine, S; Miyata, M; Sunagawa, H; Takeshima, M; Zaha, H, 2008)
"They were diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy, or with metastasis to the transverse colon."	1.35	Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. ( Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Yoshimura, M, 2008)
"To investigate the efficacy and toxicity of nedaplatin combined with tegafur in the treatment for patients with advanced esophageal cancer."	1.35	[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer]. ( Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008)
"The prognosis for advanced pancreatic cancer with peritoneal dissemination is extremely poor, and no effective standard therapy has been established."	1.35	[Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report]. ( Inaba, K; Konno, H; Okamoto, N, 2009)
"Abdominal CT scan revealed pancreatic cancer with massive ascites showing peritoneal dissemination, combined with lymph node and liver metastases."	1.35	[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases]. ( Fushida, S; Kimura, H; Mukawa, A, 2009)
"As there is no standard treatment for advanced gastric cancer refractory to first-line chemotherapy, the feasibility of S-1 plus weekly docetaxel combined with concurrent radiotherapy was evaluated."	1.35	Feasibility study of S-1 plus weekly docetaxel combined with concurrent radiotherapy in advanced gastric cancer refractory to first-line chemotherapy. ( Fujitani, K; Hirao, M; Kurokawa, Y; Tsujinaka, T; Yamasaki, H; Yoshida, K, 2009)
"We experienced this AFP-producing gastric cancer in which CR was possible by FLEP."	1.35	[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case]. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T, 2009)
"Lymph node metastasis was not found by CT scan 20 months after beginning chemotherapy."	1.35	[A case of effective treatment with UFT/LV chemotherapy for para-aortic lymph node metastasis from colonic cancer 8 years after colectomy]. ( Kimura, H; Takamura, H; Watanabe, K, 2009)
"A clinical finding was Stage IV gastric cancer of poorly differentiated adenocarcinoma."	1.35	[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy]. ( Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N, 2009)
"A 58-year-old man of unresectable gastric cancer was treated with S-1 (120 mg/body/day) after gastrojejunostomy."	1.35	[A case of advanced gastric cancer with histological complete response after S-1 chemotherapy]. ( Furuya, T; Hayashi, H; Inoue, Y; Ishigaki, N; Saeki, T; Yahara, N; Yanai, H, 2009)
"Current therapy for advanced pancreatic cancer focuses largely on gemcitabine."	1.35	Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. ( Alsamarai, S; Furuie, T; Saif, MW; Urrea, PD; Zergebel, C; Zhang, J, 2008)
"A 68-year-old man was diagnosed with gastric cancer and massive lymphadenopathy involving the perigastric, celiac axis and splenic hilum."	1.35	S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. ( Ahn, JB; Chung, HC; Jeung, HC; Jung, JY; Noh, SH; Rha, SY; Yang, WI, 2008)
"An 88-year-old man with unresectable sigmoid colon cancer due to retroperitoneal invasion and massive LN metastasis was treated with S-1 after colostomy."	1.35	[A case of unresectable sigmoid colon cancer in an elderly patient responding to S-1]. ( Matsunaga, N; Nakagawa, Y; Yanagawa, K, 2008)
"A 72-year-old male with advanced gastric cancer (cT3N2M0H0P0CY1, cStage IV) was treated with TS-1/CDDP as neoadjuvant chemotherapy."	1.34	[A case of stage IV advanced gastric cancer responding to TS-1/CDDP neoadjuvant chemotherapy which leads to a pathological complete response]. ( Hiraoka, K; Mizutani, S; Nakahara, M; Oyama, T; Takahashi, H; Tori, M; Tsujimoto, M; Uchikoshi, F; Ueshima, S; Yamagami, Y; Yoshidome, K, 2007)
"No re-growth of gastric cancer has been seen for three years with chemotherapy of TS-1."	1.34	[A case of advanced gastric cancer with liver metastases successfully treated by combination therapy of TS-1 and docetaxel]. ( Ichinari, H; Kawano, F; Matsuda, S; Mine, K; Taneda, Y; Yonei, A, 2007)
" As for the dosing method of combination chemotherapy,the patient was treated with a course of TS-1 80 mg daily divided into two doses over 21 days continuously, followed by a 14-day cessation of the drug,together with a dose of CDDP 70 mg on day 8."	1.34	[A case of advanced gastric cancer successfully treated with TS-1/CDDP combination chemotherapy, able to maintain CR for more than two years against multiple liver metastases]. ( Hayakawa, Y; Hioki, J; Irinoda, T; Kimura, T; Kobayashi, M; Matsumoto, Y; Meguro, E; Noda, Y; Takagane, A, 2007)
" We therefore reduced the dosage of TS-1 from 80 mg/body/day to 60 mg/body/day."	1.34	[A resected case of advanced gastric cancer after treatment with low-dosage TS-1]. ( Aoyagi, K; Imaizumi, T; Koufuji, K; Matono, K; Miyagi, M; Ogata, Y; Shirouzu, K; Takeda, J; Yano, S, 2007)
"Among the patients with T3/T4 gastric cancer, postoperative oral fluorouracil treatment was effective in those who were pAkt-positive."	1.34	Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. ( Ikeguchi, M; Katano, K; Murakami, D; Osaki, T; Saito, H; Tatebe, S; Tsujitani, S, 2007)
"He was diagnosed with advanced gastric cancer, T2N1H0P0M0, stage II."	1.34	[Complete response in an elderly patient with advanced gastric cancer treated with TS-1]. ( Fujiwara, S; Harada, K; Kawahara, K; Kitano, S; Moriyama, H; Noguchi, T, 2007)
"The patient was diagnosed as advanced gastric cancer (type-3) with multiple liver metastasis and obstructive jaundice."	1.34	[A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1]. ( Funada, R; Harada, K; Hasegawa, K; Homma, N; Ogata, N; Shibasaki, K; Soga, K; Uchida, M; Watanabe, T, 2007)
"Gastric small cell carcinomas are rather rare."	1.34	[A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma]. ( Hamano, R; Hirao, T; Kobayashi, T; Masuzawa, T; Shibata, K; Tokuoka, M, 2007)
"Here, we report the case of a sigmoid colon cancer patient with initially unresectable hepatic metastases showing a prolonged survival (6."	1.34	[A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases]. ( Gega, M; Hashimoto, A; Ikeuchi, H; Kuno, T; Noda, M; Oshima, T; Tanaka, K; Tsukamoto, K; Yagyuu, T; Yamamura, T; Yanagi, H; Yoshikawa, R, 2007)
"A 62-year-old woman with Barrett's esophageal cancer was hospitalized."	1.34	Successful treatment of S-1 + CDDP followed by salvage EMR for a case with metastatic Barrett's esophageal cancer. ( Azuma, M; Higuchi, K; Katada, C; Koizumi, W; Nakatani, K; Nishimura, K; Saigenji, K; Sasaki, T; Shimoda, T; Tanabe, S, 2007)
"Two patients with advanced gastric cancer who underwent gastrectomy and pathological examination were both diagnosed as having Stage IV gastric cancer with distant lymph-node metastases and peritoneal dissemination, respectively."	1.34	[Two patients with StageIV gastric cancer responding to combination therapy with S-1 and low-dose CDDP after reduction surgery]. ( Nagai, T; Ohgaki, K; Sugie, T, 2007)
" Long-term administration of S-1 may serve to prolong the survival period of patients with gastric cancer after reduction surgery, particularly in peritoneal metastasis."	1.34	[Clinical study of S-1 for advanced gastric cancer after reduction surgery]. ( Hayashi, K; Inaba, Y; Isobe, H; Miura, T; Moriya, T; Takiguchi, M; Watabe, S, 2007)
"We treated hepatic metastasis of gastric cancer with CPT-11 therapy and obtained complete remission of the hepatic tumor that has been maintained for than 2 years postoperatively."	1.34	[Complete remission of hepatic metastasis of gastric cancer with CPT-11]. ( Kohno, H; Ogawa, A; Okajima, A; Taguchi, T; Takenouchi, Y; Tsugane, K, 2007)
"We report a case of gastric cancer with ascites treated with chemotherapy."	1.34	[Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel]. ( Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H, 2007)
"We report a case of unresectable gastric cancer, who had been treated with S-1 alone for 3 years without cancerous symptoms."	1.34	[A case of long survival of unresected gastric cancer with excellent QOL administered by S-1 alone]. ( Aoki, Y; Kobayashi, J; Kuroiwa, N; Miyazaki, M; Mori, M; Morishima, Y; Nakano, M; Satomi, D; Shiramatsu, K; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yoshida, Y, 2007)
"Uracil/tegafur was stopped in December 10, 2005, and docetaxel (taxotere) 50mg/m2 was given in December 12, 2005."	1.34	[Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer]. ( Bandoh, S; Kanaji, N, 2007)
"Thirty-seven patients with advanced esophageal cancer were admitted between March 2002 and April 2005."	1.34	Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. ( Choi, CW; Choi, IK; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sung, HJ, 2007)
"We report a case of advanced gastric cancer with multiple liver metastases,in which a complete resection was performed following a bypass operation and chemotherapy."	1.34	[Complete resection of advanced gastric cancer with multiple liver metastases following a bypass operation and one year of chemotherapy]. ( Hatakeyama, K; Kobayashi, T; Kurosaki, I; Kurosaki, R; Matsuo, H; Ohashi, M; Yajima, K, 2007)
"A 65-year-old man who had AFP producing gastric cancer with massive lymph-node metastasis was admitted to our institution."	1.34	[A case of curatively resected AFP producing gastric cancer with massive lymph node metastasis effectively treated by neoadjuvant-chemotherapy of S-1 and CDDP]. ( Amano, S; Aramaki, O; Kano, H; Kawasaki, A; Kuboi, Y; Mimatsu, K; Ogura, M; Oida, T, 2007)
"We report a recurrent case of gastric cancer with para-aortic lymph node metastasis that showed a marked response to systemic chemotherapy consisting of S-1 alone."	1.34	[Marked response to S-1 chemotherapy for para-aortic lymph node metastasis arising from gastric cancer]. ( Chikuba, A; Chikuba, H; Nakamoto, M; Nezu, M; Shimamura, H; Suzuki, T; Takiue, T; Teraishi, F, 2007)
"We report here a case of synchronous dermoid cyst with secondary malignant tumor and uterine endometrial adenocarcinoma that responded to UFT."	1.33	[A case of synchronous double cancer responding to UFT--dermoid cyst with secondary malignant transformation and uterine endometrial adenocarcinoma]. ( Fukai, H; Maruyama, A; Matsumoto, H; Sakamoto, H; Takami, M; Takimoto, T; Togo, Y; Yamamoto, T, 2005)
"In general, treatment for gastric cancer with peritoneal dissemination or recurrent gastric cancer is outside the scope of surgery."	1.33	[A case of a nonresected gastric cancer with peritoneal dissemination maintained on TS-1 and docetaxel combination chemotherapy with good QOL]. ( Kawasaki, H; Kobori, H; Maruyama, M; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Yamada, K, 2005)
" 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a."	1.33	[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005)
"A 58-year-old man with gastric cancer who had undergone distal gastrectomy on February 8, 2001 was revealed to have anorexia, and was diagnosed with a local recurrence in anastomosis by upper GI examination in August 2003."	1.33	[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report]. ( Fujii, M; Kasakura, Y; Kochi, M; Morishita, Y; Sato, K; Takayama, T; Yamagata, M, 2005)
"She was diagnosed as remnant gastric cancer with multiple bone metastasis and peritoneal dissemination."	1.33	[A case of remnant gastric cancer with multiple bone metastasis and peritoneal dissemination; efficacy of combination therapy of docetaxel and TS-1]. ( Hamai, Y; Hihara, J; Tanabe, K; Toge, T; Ukon, K; Yoshida, K, 2005)
"A 59-year-old male patient with rectal cancer 2 cm in diameter (T2) at the peritoneal reflection with suspicious left lateral node metastasis was treated with 400 mg of preoperative oral uracil and tegaful (UFT) for 5 weeks, 5 days a week in combination with concomitant radiotherapy of 45 Gy per 25 fractions for 5 weeks."	1.33	Neoadjuvant therapy of rectal cancer using oral tegaful-uracil (UFT) plus concomitant radiotherapy--a case report. ( Arihiro, K; Emi, M; Hironaka, K; Kawabuchi, Y; Ohshita, A; Sakatani, A; Yamaguchi, Y, 2005)
"For this gastric cancer, clinical Stage IIIA (cT3N1HOPOMO), neoadjuvant chemotherapy with TS-1/CDDP was planned."	1.33	[A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP chemotherapy]. ( Inoue, S; Kawahara, Y; Kitamura, M; Kusano, T; Shioiri, T; Umekita, N; Warabi, M, 2005)
"To investigate the effect and feasibility of concurrent radiation and chemotherapy combined with endorectal brachytherapy in T3 rectal cancer with complete pathologic remission as end point."	1.33	Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. ( Bisgaard, C; Hansen, JW; Jakobsen, A; Lindebjerg, J; Mortensen, JP; Rafaelsen, SR, 2006)
"We reported 2 cases with advanced gastric cancer, successfully treated with TS-1 and CDDP."	1.33	[Two cases of advanced gastric cancer, successfully treated with TS-1/CDDP combination chemotherapy--case report]. ( Ando, K; Ishihara, C; Ishiwa, N; Morinaga, S; Noguchi, Y; Ogoshi, T; Shotsu, M; Takeda, A; Yamamoto, Y; Yoshida, S; Yoshikawa, T, 2005)
"A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt."	1.33	[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005)
" In conclusion, individual dose adjustment using pharmacokinetic study of 5-FU might be beneficial to patients with impaired renal function."	1.33	[A trial of TS-1 administration on the basis of the pharmacokinetic study for an advanced gastric cancer patient with impaired renal function]. ( Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kawasaki, T; Kishimoto, T; Kondo, M; Masutani, S; Nakayama, T; Oshiro, R; Takemoto, H; Tanaka, J; Tatsuta, M; Yamamoto, K, 2005)
" The patient was treated with TS-1 combined with CPT-11."	1.33	[A case of an increase in resectability with preoperative chemotherapy TS-1 combined with CPT-11 for unresectable rectal cancer in downstaging]. ( Doi, M; Egawa, T; Hayashi, S; Kitano, M; Nagashima, A; Yoshii, H, 2005)
"These results suggest that gastric cancer,in which liver metastasis is considered to be a prognostic factor,can be effectively treated by combination therapy with hepatic arterial infusion therapy, followed by thermochemotherapy for the primary lesion."	1.33	[A case of gastric cancer with multiple liver metastases effectively treated by hepatic arterial infusion of MMC, TS-1/CDDP therapy, and thermotherapy]. ( Aoki, T; Hamaya, M; Kouno, T; Nishida, J; Ogata, T; Sato, S; Seo, K; Tsuchida, A; Yoshida, K, 2005)
"We report herein a case with stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy."	1.33	[A case of stage IV gastric cancer previously treated with TS-1 completely responding to second-line chemotherapy with weekly paclitaxel therapy]. ( Jingu, K; Kagaya, A; Ochiai, T; Sasagawa, K, 2005)
"One hundred fifteen patients with rectal cancer were treated with oral 5-fluorouracil or Tegafur with preoperative radiotherapy, surgery, and intraoperative electron beam radiation therapy to identify potential pre- and on-treatment characteristics that might be of prognostic value for disease outcome."	1.33	Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. ( Alvarez, E; Calvo, FA; Cortés, J; Del Valle, E; Díaz-González, JA; García-Sabrido, JL; Gómez-Espí, M; Muñoz-Jiménez, F, 2006)
"We report a case of gastric cancer with peritoneal recurrence that responded to chemotherapy with paclitaxel and TS-1."	1.33	[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1]. ( Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N, 2006)
"Endoscopic findings revealed type 3 gastric cancer."	1.33	[A case of gastric cancer with DIC caused by multiple bone metastases treated with TS-1]. ( Fujishiro, R; Ichinose, T; Naruse, Y; Sakamoto, R; Yamazaki, A, 2006)
"A resected case of gastric cancer is described."	1.33	[A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. ( Aita, K; Moon, Y; Oshiro, Y; Yamamoto, Y, 2006)
"Patients with locally advanced rectal cancer (LARC) have a poor prognosis."	1.33	[New treatment strategies for patients with primary non-resectable rectal cancer]. ( Baatrup, G; Jensen, HA; Kronborg, O; Pfeiffer, P, 2006)
" Because it was the yearend, we selected neoadjuvant TS-1 combined with CDDP therapy."	1.33	[Advanced gastric cancer responding to pathological CR after neoadjuvant TS-1 combined with CDDP therapy--report of a case]. ( Nakagawa, S; Nashimoto, A; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H, 2006)
" We carried out 4-week administration of 80-120 mg/day of TS-1 according to body surface area, followed by a 2-week discontinuation, then repeated administration which adjusting the dosage according to the incidence of side effects, and discussed the antitumor effects and adverse events."	1.33	[Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer]. ( Hatori, S; Imada, T; Kunisaki, C; Makino, T; Ohshima, T; Rino, Y; Suda, T; Takanashi, Y; Yamada, R; Yamazaki, Y, 2006)
"We report a case of N 3 gastric cancer successfully treated by TS-1 followed by curative resection."	1.33	[A case of N3 gastric cancer successfully treated by TS-1 followed by curative resection]. ( Hara, S; Hashizume, S; Ishikawa, H; Iwasaki, K; Kamohara, R; Kondou, M; Minami, H; Sumida, Y; Tokunaga, T; Yoshida, K, 2006)
"Gastrofiber-scopy revealed that type 3 gastric cancer was widespread in the lesser curvature."	1.33	[A resected case of advanced gastric cancer with multiple liver metastasis responding to preoperative TS-1/CDDP chemotherapy]. ( Kagawa, I; Matsumoto, Y; Nishiwaki, K; Ohi, A, 2006)
"Two metastatic colonic cancer patients were successfully treated by the combination therapy of UFT plus oral Leucovorin (UFT/LV)."	1.33	[Two metastatic colonic cancer patients successfully treated by combination therapy of tegafur/uracil (UFT) and oral Leucovorin]. ( Ando, T; Goto, H; Ina, K; Inagaki, J; Ito, A; Kataoka, T; Kato, H; Nagao, S; Niwa, Y; Ohkita, T, 2006)
"In two patients with advanced pancreatic cancer with cervical lymph node or liver metastasis and no indication of pancreatic resection and radiotherapy, oral treatment with S-1 (an anti-cancer agent of fluoropyrimidine derivative) exerted high anti-tumor activity on the metastatic lesions."	1.33	[Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy]. ( Funakoshi, A; Senju, T; Sumii, T, 2006)
"We report two metastatic pancreatic cancer patients who showed marked tumor shrinkage following administration of the oral fluorinated pyrimidine anticancer drug, S-1."	1.33	[Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]. ( Ikeda, M; Ueno, H, 2006)
"Grade 3 neutropenia was observed, but no other severe toxicities were noted."	1.33	[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report]. ( Boku, N; Fukutomi, A; Yoshino, T, 2006)
"Further examination showed an advanced gastric cancer with peritoneal dissemination."	1.33	[A case of advanced gastric cancer with peritoneal dissemination responding remarkably to TS-1/CDDP combination chemotherapy]. ( Asagoe, K; Azechi, H; Inoue, F; Ishii, K; Katsurada, A; Kondo, M; Nishikawa, K; Nishiura, H; Nonami, M; Otani, Y; Saiga, T; Shigemori, M; Suwa, H; Tojo, M, 2006)
"A 38-year-old female patient with gastric cancer, of which histological type was a poorly differenciated adenocarcinoma and a clinical finding was T3N1MO (Stage IIIA), underwent total gastrectomy with D2 lymphadenectomy as the surgical treatment."	1.33	[A case of complete remission of carcinomatous ascites refractory for TS-1 monotherapy treated with TS-1 plus paclitaxel combined therapy for gastric cancer]. ( Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Kondo, M; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M; Yamamoto, K, 2006)
"Paclitaxel was administered to 4 patients at a weekly dose of 80 mg/m2/day for three weeks followed by a one week interval."	1.32	[Treatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1]. ( Chida, N; Imai, G; Ishibashi, J; Iwabuchi, M; Matsuda, Y; Mochida, A; Shiina, M; Suzuki, S; Suzuki, T; Tadokoro, K; Takahashi, H; Yamada, K; Yokoyama, H, 2003)
"A 54-year-old man with colon cancer underwent hemicolectomy."	1.32	Therapy-related erythroleukemia caused by the administration of UFT and mitomycin C in a patient with colon cancer. ( Miyazaki, M; Nakamori, Y; Shinohara, K; Taguchi, A; Tominaga, T, 2003)
"Survival of patients with advanced gastric cancer with Krukenberg's tumor is poor."	1.32	[A case of type 4 gastric cancer, diagnosed after operation for Krukenberg's tumor, treated by TS-1 plus low-dose cisplatinum]. ( Akiba, Y; Aoki, D; Hibi, T; Ishii, H; Kato, S; Mukai, M; Naito, K; Takada, Y; Watanabe, C, 2003)
"The prognosis and QOL of unresectable pancreatic cancer are very poor."	1.32	[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1]. ( Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y, 2003)
"We report a case of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1."	1.32	[A case of advanced gastric cancer resected after successful treatment with the novel oral anticancer drug TS-1]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Tamura, M; Tsuge, T; Watabe, S, 2003)
"A 67-year-old man with gallbladder cancer was treated by cholecystectomy and extrahepatic bile duct resection with regional lymph node dissection."	1.32	[A case of para-aortic lymph node recurrence of gallbladder cancer completely responding to single drug (UFT) chemotherapy]. ( Kido, S; Kitahara, K; Magata, S; Matsuyama, S; Miyazaki, K; Motoyama, K; Takei, M, 2003)
"S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis."	1.32	Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. ( Boku, N; Doi, T; Hamamoto, Y; Kawai, H; Mera, K; Muto, M; Nagashima, F; Ohtsu, A; Sano, Y; Yano, T; Yoshida, S, 2003)
"We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration."	1.32	[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003)
"Preoperative diagnosis was stage IV gastric cancer (T3 (SE) H0 P0 N3), and we considered a curative operation impossible."	1.32	[A case of advanced gastric cancer with abdominal paraaortic lymph node swelling successfully resected following neoadjuvant chemotherapy of TS-1 and low-dose cisplatin]. ( Kanehiro, T; Morifuji, M; Murakami, Y; Sasaki, M; Sueda, T; Uemura, K; Yokoyama, T; Yokoyama, Y, 2003)
"We treated a patient with gastric cancer considered to be unresectable due to peritoneal metastasis, who responded remarkably to treatment with TS-1."	1.32	[A case of peritoneal metastasis of gastric cancer responding to TS-1, administered for four consecutive weeks with two-week rests]. ( Adachi, I; Emoto, T; Fujii, M; Fujikawa, M; Kamei, A; Komaki, T; Naka, Y; Nezu, R; Yokota, T; Yoshikawa, K; Yoshioka, Y, 2003)
" TS-1 was administered with the usual dosage and dose regimen."	1.32	[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital]. ( Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H, 2003)
" Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)."	1.32	[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003)
" Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation."	1.32	[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. ( Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003)
"We report two head and neck cancer patients who responded to TS-1."	1.32	[Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1]. ( Horiuchi, C; Kagesato, Y; Kawai, S; Mikami, Y; Mochimatsu, I; Tanigaki, Y; Tsukuda, M, 2003)
"A 62-year-old advanced gastric cancer patient with bulky N2 lymph node metastases was treated by neoadjuvant chemotherapy with TS-1 and CDDP."	1.32	[A case of advanced gastric cancer responding to neoadjuvant TS-1/CDDP therapy]. ( Kameyama, H; Nashimoto, A; Ohta, T; Takii, Y; Tanaka, O; Tsuchiya, Y; Yabusaki, H, 2003)
"This was diagnosed as inoperable gastric cancer, and gastro-jejunostomy was performed."	1.32	[A case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma]. ( Fujita, T; Fukuda, K; Komatsubara, S; Mano, M; Nishi, H; Ohmura, Y; Takao, T; Yano, T, 2003)
"A 72-year-old man with common bile duct cancer was treated by pylorus preserving pancreatoduodenectomy with D3 lymph node dissection and preventive radiotherapy at hepaticojejunostomy."	1.32	[A case of liver metastatic recurrence of bile duct cancer completely responding to single drug, UFT, chemotherapy]. ( Hirano, T; Kitahara, K; Magata, S; Matsuyama, S; Miyazaki, K; Mori, M; Shimonishi, T, 2004)
"An umbilical metastasis of gastric cancer is known as Sister Mary Joseph's nodule."	1.32	[A case of gastric cancer with umbilical metastasis that responded to TS-1 with low-dose cis-platinum]. ( Fukunaga, S; Hirakawa, K; Inoue, T; Ishikawa, T; Kato, Y; Nakata, B; Nishiguchi, Y; Ohira, M; Takashima, T; Yamagata, S; Yashiro, M, 2004)
"Synchronous esophageal and gastric cancer were diagnosed by endoscopy and barium swallow."	1.32	[A case of synchronous esophageal and gastric cancer successfully treated by combination TS-1/CDDP therapy with irradiation]. ( Fujiwara, Y; Fukuhara, K; Harada, S; Kaneko, M; Kinoshita, H; Lee, S; Nishizawa, S; Osugi, H; Taguchi, S; Takemura, M; Tanaka, Y, 2004)
" He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11."	1.32	[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004)
"We report a patient with unresectable gastric cancer who was effectively treated with an anticancer drug, S-1, after receiving an improved gastrojejunostomy."	1.32	A long-surviving patient with unresectable advanced gastric cancer responding to S-1 after receiving improved gastrojejunostomy. ( Amano, S; Kaneda, H; Kanou, H; Kawasaki, A; Kuboi, Y; Mimatsu, K; Oida, T, 2004)
"We report a case of advanced gastric cancer with bulky N2 lymph node metastases resected after successful treatment with novel oral anticancer drug TS-1 as a neoadjuvant chemotherapy (NAC)."	1.32	[A case of advanced gastric cancer with bulky N2 lymph node metastases resected after successful treatment with TS-1]. ( Hirata, K; Inoue, D; Kashiwagi, K; Maeda, H; Sasaki, K; Shibuya, H; Takashima, T, 2004)
"The patient was a 61-year-old man with rectal cancer and multiple pulmonary metastases."	1.32	[A case of multiple pulmonary metastases from rectal cancer effectively treated by TS-1 and low-dose CDDP therapy]. ( Ishimura, K; Karasawa, Y; Maeta, H; Ushiyama, T; Wakabayashi, H, 2004)
"Although the prognosis of recurrent gastric cancer with peritoneal dissemination was extremely poor, this case might suggest a possibility that intensive therapies are useful in maintaining the quality of life and improving survival."	1.32	[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T, 2004)
"Since gastric cancer was detected, he was referred to our department."	1.32	[A case of gastric cancer with paraaortic lymph node metastasis responding to TS-1/CDDP combination therapy]. ( Aiba, M; Hamaguchi, K; Katsube, T; Konno, S; Murayama, M; Naritaka, Y; Obu, M; Ogawa, K; Shimakawa, T; Yagawa, Y, 2004)
"A Case of Advanced Gastric Cancer with Multiple Liver Metastases Successfully Treated with TS-1 and CDDP: Akihiro Tsukahara, Kazuhiro Kaneko and Syuji Tanaka (Dept."	1.32	[A case of advanced gastric cancer with multiple liver metastases successfully treated with TS-1 and CDDP]. ( Kaneko, K; Tanaka, S; Tsukahara, A, 2004)
" Beginning on August 9, 1999, TS-1 was administered in a dosage of 50 mg bid, but it was later learned that the patient had ingested only half of that TS-1 dosage (i."	1.31	[A case of residual gastric cancer accompanied by esophageal invasion in which residual lesions were eradicated by half-dose administration of TS-1]. ( Abe, S; Kitago, M; Kojima, M; Kurihara, H; Ogihara, T; Sasanuma, H; Tamura, H; Wada, M, 2002)
"Computed tomography (CT) showed gastric cancer with extensive paraaortic lymph node metastasis."	1.31	[A case of gastric cancer with paraaortic lymph node metastasis responding to TS-1/CDDP as neoadjuvant chemotherapy]. ( Furukawa, J; Katsumoto, Y; Maruyama, K; Maruyama, N; Nakaguchi, K; Nakamura, M; Sue, F; Tanaka, J; Yokouchi, H; Yoshihara, W, 2002)
"We report three gastric cancer patients responding to chronomodulation chemotherapy (tegafur + cisplatin + Isovorin) based on circadian rhythms plus a new antitumor drug, CPT-11."	1.31	[Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration]. ( Hirose, T; Kobayashi, A; Yamada, T, 2002)
"We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy."	1.31	[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization]. ( Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y, 2002)
"We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)."	1.31	[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002)
"We encountered a patient with gastric cancer for whom oral administration of S-1 was effective, and we report this case."	1.31	Advanced gastric cancer with liver metastases successfully treated with S-1. ( Hirayama, Y; Takabayashi, H; Takeuchi, T; Tanaka, T; Watanabe, S, 2002)
"This is a rare case of gastric cancer showing complete response to chemotherapy using a peroral carcinosatatic alone."	1.31	[A case of advanced gastric cancer showing complete response to chemotherapy of peroral carcinostatic only]. ( Endo, I; Iijima, K; Ikeya, S; Imai, J; Kamiya, T; Kashimura, J; Kuroki, M; Ojima, T; Saito, Y; Sato, K; Takahashi, M, 2002)
" Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co."	1.31	[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. ( Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002)
"Advanced gastric cancer (AGC) with liver metastasis has a poor prognosis."	1.31	[A case of metastatic gastric cancer treated with CDDP plus TS-1 and surgical resection]. ( Ezumi, K; Furukawa, H; Imamura, H; Ishida, H; Kato, H; Kawasaki, T; Masuda, N; Masutani, S; Shimizu, J; Tatsuta, M, 2002)
"A case of an unresected, advanced gastric cancer with Sister Mary Joseph nodule was presented."	1.31	Complete response of Sister Mary Joseph Nodule from gastric adenocarcinoma treated with combination chemotherapy of low-dose S-1 and cisplatin. ( Hayashi, H; Hayashi, Y; Kamata, T; Kanno, M; Michiwa, Y; Minatoya, G; Onishi, I; Takeda, T; Ueda, Y, 2002)
"We report a case of unresectable rectal cancer in a 53-year-old male treated with chemoradiation."	1.31	[Long-term complete response in a case of unresectable rectal cancer following chemoradiation]. ( Musha, N; Oka, K; Saito, H; Sando, N; Sasaki, M; Setu, M; Setu, Y; Sunami, E, 2000)
"According to the General Rules for Gastric Cancer Study, the patient belongs to the class of complete response."	1.31	[A case of complete regression of liver metastases by treatment with Futraful supposition]. ( Bandoh, T; Fujiwara, M; Isoyama, T; Nagaoka, S; Noji, M; Takemura, T, 2000)
"5-fluorouracil (5-FU) was given 200 mg/day for 26 days orally."	1.31	[A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy]. ( Nashimoto, A; Tanaka, O; Yabusaki, H, 2000)
"We report a case of advanced rectal cancer accompanied by unresectable liver metastasis in which remission has been achieved for 7 years."	1.31	[A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective]. ( Baba, H; Kikunaga, H; Matsudo, A; Miura, H; Morisue, A; Nakai, H; Osakabe, Y; Sotome, K; Takao, M, 2000)
"For cases of liver metastasis from colon cancer that are non-resectable due to multiple liver metastases, other organ metastases (lung, bone, brain etc."	1.31	[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11]. ( Kobayashi, A; Yamaguchi, M, 2000)
"Tegafur is a prodrug that is converted to 5-fluorouracil (5-FU) and has been reported to be less toxic and to have a higher therapeutic index."	1.31	Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Hsu, TC; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, HS; Wang, WS; Yang, SH; Yen, CC, 2000)
"A 67-year-old female with rectal cancer and multiple liver metastases underwent low anterior resection by total mesorectal excision (TME), cholecystectomy and hepatic arterial cannulation in June 1995."	1.31	[Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)]. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2001)
"Although prostate cancer initially responds well to endocrine therapy, it becomes resistant to the therapy a few years later, and is called hormone-refractory cancer."	1.31	[Long-term survival of hormone-refractory prostate cancer: a case report]. ( Fujimoto, N; Harada, S; Hida, T; Matsumoto, T, 2001)
"Tegafur is a prodrug of 5-FU and is a component of S-1, another oral fluoropyrimidine active in a variety of solid tumors."	1.31	Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. ( Elasmar, SA; Hoff, PM; Saad, ED, 2001)
"Considering that interstitial pneumonia has also been reported with 5-FU, it is necessary in the future to clarify which component of this drug is directly related to interstitial pneumonia."	1.31	Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. ( Ishizuka, S; Kasuga, I; Kunisawa, A; Kurakawa, E; Minemura, K; Ohyashiki, K; Utsumi, K; Yoshida, T, 2001)
"We report two elderly gastric cancer patients responding to chronomodulation chemotherapy (tegafur + cisplatin + Isovorin) based on circadian rhythms plus a new antitumor drug, S-1."	1.31	[Two elderly patients with advanced gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by oral administration of S-1]. ( Kobayashi, A; Yamaguchi, M, 2001)
"We report a case of recurrent gastric cancer that responded significantly to the short-term administration of TS-1."	1.31	[Case report: a recurrent gastric cancer in the terminal stage, associated with obstructive jaundice which responded significantly to oral administration of TS-1]. ( Fukuda, H; Sugihara, Z; Tasaka, K; Tomofuzi, Y, 2001)
"We report a case of advanced gastric cancer producing Alpha Fetoprotein (AFP) with multiple liver metastases in which TS-1 is effective."	1.31	[A case of advanced gastric cancer producing alpha fetoprotein with multiple liver metastases responding to TS-1 after TAE]. ( Hayashi, Y; Kawasaki, Y; Kobayakawa, K; Ohtsuru, M; Oka, H; Okazaki, M; Yamamura, J; Yamamura, M; Yasuda, S, 2001)
"A patient with advanced gastric cancer complicated with liver and lymph node metastases was successfully treated with a novel oral anticancer drug, TS-1, TS-1 was administered at a dose of 100 mg/day."	1.31	[A case of advanced gastric cancer successfully treated with TS-1]. ( Funakoshi, A; Iguchi, H; Matsuo, S; Miyagi, Y; Ouchi, J; Sumii, T; Uchimura, K; Yokota, M, 2002)
" We report three cases of advanced gastric cancer treated using TS-1 in combination with a low-dose of cisplatinum (CDDP) that well responded."	1.31	[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum]. ( Gomi, T; Kanaya, S; Katayama, T; Momoi, H; Ohtoshi, M; Tamaki, N; Wada, Y, 2002)
"We present the case of a 72-year-old man with gastric tube cancer accompanied by multiple liver metastases, after esophagectomy for esophageal cancer, whose quality of life (QOL) was improved with a small dosage of TS-1."	1.31	[A patient with advanced gastric cancer in the gastric tube whose QOL was improved by TS-1]. ( Ajisaka, H; Fujita, H; Inokuchi, M; Iwata, K; Kaji, M; Konishi, K; Maeda, K; Miwa, A; Yabushita, K; Yamamoto, S; Yoshioka, I, 2002)
" He was treated postoperatively with arterial infusion pharmacokinetic modulating chemotherapy (PMC) and venous infusion CPT-11 (modified PMC)."	1.31	[A case of rectal cancer with multiple liver metastases that responded dramatically to pharmacokinetic modulating chemotherapy/CPT-11 therapy]. ( Dan, T; Kitayama, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Tanabe, H; Yamasaki, H, 2002)
"A patient with advanced gastric cancer responded remarkably to UFT combined with CDDP."	1.30	[A case of advanced gastric cancer successfully treated by UFT and CDDP followed by surgical resection proving cancer cell disappearance in the stomach]. ( Akao, M; Azuma, M; Inukai, A; Manabe, T; Matsugaki, K; Muramoto, M; Nakai, T; Ogino, K, 1998)
"Pulmonary metastases were not inhibited by the treatment with AHCC plus UFT, whereas metastases to axillary lymph nodes (LN) were obviously inhibited."	1.30	Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. ( Hosokawa, M; Kobayashi, M; Kuramitsu, Y; Li, YQ; Matsushita, K; Obara, M; Ohiro, Y, 1998)
" These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5."	1.30	Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ( Brown, N; Covington, W; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Pazdur, R, 1998)
"A 74-year-old Japanese woman with early gastric cancer was successfully treated with uracil and tegafur (UFT)."	1.30	Complete response of early gastric cancer to uracil and tegafur. ( Akahoshi, K; Chijiiwa, Y; Hamada, S; Hara, K; Matsui, N; Nakamura, K; Nawata, H, 1998)
"We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy."	1.29	[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy]. ( Ikeda, K; Shibata, N; Tamai, M, 1995)
"A 47-year-old man with ascending colon cancer with multiple liver metastases and bone metastasis (VII thoracic vertebra) showed a remarkable response to the combination therapy of tegafur and cisplatin."	1.29	[A case of remarkable response of colon cancer with multiple liver and bone metastasis treated with tegafur and cisplatin]. ( Arima, S; Futami, K; Hara, F; Harada, Y; Inada, S; Kotoh, T; Nishida, T; Tateishi, S; Yamasaki, K, 1995)
"A 64-year-old women with gallbladder cancer was treated by extended cholecystectomy and regional lymph node dissection."	1.29	[A case of retroperitoneal lymph node recurrence with gallbladder cancer responding to UFT and CDDP combination chemotherapy]. ( Arima, S; Futami, K; Kotoh, T, 1994)
"We report a case of early gastric cancer with Virchow's node metastasis."	1.29	[A case of early gastric cancer with Virchow's node metastasis, effectively treated by high dose of UFT]. ( Eguchi, A; Fukano, M; Furuta, T; Haraguchi, M; Iwao, Y; Tsuboi, S, 1993)
"To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients."	1.29	A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993)
"We here reported a case of advanced gastric cancer remarkably responding to preoperative short-term UFT-E chemotherapy."	1.29	[A case of advanced gastric cancer remarkably responding to preoperative UFT-E therapy]. ( Iijima, K; Iwazaki, R; Maehiro, K; Miwa, H; Mizobuchi, N; Okura, R; Ono, Y; Ota, K; Sato, K; Sato, N; Urabe, M; Wada, R, 1996)
"A 79-year-old man having advanced gastric cancer with liver metastasis was treated by gastric dissection and gastro-jejunostomy."	1.29	[Successful UFT-E granule and 5-FUCDDP combination therapy for an unresectable advanced gastric cancer complicated with liver metastasis]. ( Hyakuna, Y; Kushibiki, K; Matsuoka, H; Shimada, M; Yokomichi, H, 1996)
" Pharmacokinetic examination after intravenous injection of low-dose MMC (0."	1.29	A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996)
"However, metastatic bone tumors from gastric cancer usually resist any treatments."	1.28	[A case of gastric cancer with recurrent bone metastases successfully treated with induced hypertension chemotherapy using cisplatin]. ( Furuya, K; Kashu, Y; Kiyasu, Y; Moriuchi, A; Sakai, K; Satoh, H; Shigematsu, S; Tanaka, T, 1992)
"A 74-year-old man with advanced gastric cancer of Borrmann type III and liver metastasis was treated by combined administration of UFT (400 mg/day, p."	1.28	[A case of advanced gastric cancer with liver metastasis completely responding to a combined immunochemotherapy with UFT, mitomycin C and lentinan]. ( Hatayama, H; Kitamura, H; Mashiko, H; Satoh, J, 1992)
"To remove regionally recurrent cancer of the rectum completely, more radical extensive resections were attempted than the conventional ones in 35 patients."	1.28	Extensive en bloc resection of regionally recurrent carcinoma of the rectum. ( Iijima, Y; Kotoura, Y; Maetani, S; Nishikawa, T; Shikata, J; Tobe, T; Yamamura, T, 1992)
"Influencing factors of recurrence in rectal cancer, such as depth of invasion, ew, vessel invasion (ly, v) and lymph node involvements were improved in the irradiated group, especially in effective cases, as compared with the non-irradiated group."	1.28	[Histopathological findings in rectal carcinomas undergoing preoperative irradiation combined with chemotherapy]. ( Takiguchi, N, 1992)
"In cases of advanced ovarian cancer, intermittent CDDP therapy (ICDDPT) was applied after the first operation and induction chemotherapy, and its efficacy and limit were studied."	1.28	[Significance of intermittent CDDP therapy for improving long-term prognosis in patients with advanced ovarian cancer]. ( Kawabata, M; Matsumoto, Y; Nakano, M; Sugawa, T; Tsuda, K; Umesaki, N; Yamamoto, A, 1991)
"A case of local recurrence of rectal cancer was successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension."	1.28	[A case of local recurrence of rectal cancer successfully treated by UFT combined with two-route CDDP chemotherapy under the AT-II induced hypertension]. ( Ishizawa, T; Iwashige, H; Maenohara, S; Mure, H; Shimazu, H; Takao, S; Yamada, K, 1991)
"A 59-year-old man with a gastric cancer underwent a laparotomy and was found to have an unresectable tumor that formed a large mass with metastatic lymph nodes around the aorta."	1.28	[An advanced gastric carcinoma which responded to combined administration of mitomycin C, FT-207, and lentinan immunochemotherapy]. ( Adachi, M; Kobori, O; Nomura, K; Sano, T, 1990)
"Mitomycin C (MMC) is an alkylating agent which has been associated with microangiopathic hemolytic anemia and acute renal failure, with an overall incidence between 2 and 10%."	1.28	Silent renal microangiography after mitomycin C therapy. ( Botey, A; Darnell, A; González-Clemente, JM; Poch, E; Revert, L; Torras, A, 1990)
"In treating advanced gastric cancer cases, 100 mg/m2 of cisplatin (CDDP) was given to such patients by means of a 24 hr continuous iv infusion once a month."	1.28	[UFT/CDDP treatment in advanced gastric cancer--case report]. ( Horiuchi, Y; Ibayashi, J; Koyama, Y; Nagai, H; Ohkita, T; Suga, S, 1989)
"Sixteen cases of gastric cancer with liver metastases (H2 less than) as group A, fifteen with distant peritoneal metastases (P2 less than) as group B, twenty-five with distant lymph nodes metastases (N3 less than) as group C, twenty-eight with two prognostic factors as group D, and seven with three factors as group E were treated."	1.28	[Comparative study of tegafur (p.o.) and mitomycin C (MMC) plus tegafur in cases of unresectable gastric cancer]. ( Ishiguro, E; Iwa, T; Kawaura, Y; Munemoto, Y; Omura, K; Sasaki, M; Sekido, N, 1989)
"A 58-year-old woman who was inoperable because of S3 (pancreas and colon) and P1 at the initial operation was treated with UFT, ADM and MMC at a dosage of 242."	1.28	[An unresectable gastric cancer radically resectable following UFT, ADM, MMC therapy]. ( Hayashi, S; Kamejima, N; Kasugai, T; Kataoka, M; Kureyama, Y; Masaoka, A; Mitsui, T; Taniwaki, S; Tsuji, H; Watarai, N, 1989)
"We report a case of advanced gastric cancer with Virchow's node metastasis which responded to concomitant plasma exchange and immunochemotherapy."	1.28	[A case of advanced gastric cancer with Virchow's node metastasis, responding to concomitant plasma exchange and immunochemotherapy]. ( Iga, C; Kawashima, Y; Nishimura, J; Okajima, K; Sakuramoto, K; Toyoda, M, 1989)
"One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks."	1.27	[Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984)
"Thirty patients with advanced gastric cancer were treated with a combination chemotherapy consisting of adriamycin 20-30 mg/m2 iv day 1 q3wks, mitomycin C 2."	1.27	[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Okada, Y; Usui, N, 1983)
"Tegafur was administered orally in two or three divided doses."	1.27	Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
"Three rectal cancer patients with partial response (PR) were obtained by oral administration of 800-1200 mg/day of SF-SP."	1.27	[The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients]. ( Endo, S; Furukawa, R; Katsumi, S; Mukae, S; Sato, T; Sekine, S; Watanabe, I; Watanabe, S, 1984)
"For the response of advanced gastric cancer to chemotherapy in the National Cancer Center Hospital, the combined use of UFT and Mitomycin C gave the highest rate, 46%."	1.27	Radiation therapy for advanced gastric cancer. ( Akine, Y; Egawa, S; Hijikata, J; Kajiura, Y; Kitagawa, T; Ogino, T; Tsukiyama, I; Yamashita, K, 1988)
"Twenty-six patients with unresectable gastric cancer, divided into two groups, were treated with combination chemotherapy of FEP (14 patients) or FAP (12 patients)."	1.27	[FEP and FAP combination chemotherapy in advanced gastric cancer. Research Group for Gastric Cancer]. ( Hayakawa, M; Hayashi, N; Kaneshiro, K; Morise, K; Oka, Y; Suga, S; Suzuki, T; Tsunekawa, H; Umemura, K; Yoshida, H, 1988)
"An aged female patient with inoperable gastric cancer was treated with a combined chemotherapy using UFT and Mitomycin C."	1.27	[A case of an aged woman with advanced gastric cancer which dramatically responded to combined chemotherapy with UFT and mitomycin C]. ( Adachi, M; Sasaki, M, 1986)
" The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug."	1.27	[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. ( Maeda, T, 1986)
"A case of relapsed gastric cancer postoperatively presenting obstructive jaundice due to metastases in the hepatic portal and periaortic lymph nodes and multiple lung metastases was given OK-432 continuously i."	1.27	[A case of relapsed gastric cancer treated successfully by chemotherapy--lung metastasis and relapsed cancer in the hepatic portal system]. ( Kawahara, M; Matsuo, T; Nagamatsu, Y; Nakarai, I; Shinoda, A, 1986)
"A chemosensitivity test for UFT and FT-207, which are used in long-term administration clinically, was investigated for prediction of clinical response."	1.27	[In vivo chemosensitivity test for UFT and FT-207. I--Subrenal capsule assay]. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Nosoh, Y; Tohge, T; Yamaguchi, M, 1987)
" UFT inhibited significantly the tumor growth of CH-I established from colon cancer in which the prolongation of life span has been obtained by clinical long-term administration of UFT."	1.27	[In vivo chemosensitivity test for UFT and FT-207. II. Chemosensitivity test on human tumor xenografts transplanted in nude mice]. ( Hattori, T; Hirabayashi, N; Niimi, K; Niimoto, M; Nishiyama, M; Nosoh, Y; Toge, T; Wang, DC; Yamaguchi, M, 1987)
"Thirteen patients with metastatic brain tumors were treated with two different chemotherapy regimens."	1.27	[The effect of combined chemotherapy with UFT, cis-platinum and aclarubicin in metastatic brain tumors]. ( Kida, Y; Kobayashi, T; Tanaka, T, 1987)
"The tumor was revealed to be a sigmoid colon cancer with multiple metastasis to both halves of the liver."	1.27	[A case of remarkable regression of a colonic cancer involving metastasis to the liver as a result of FT-207 treatment]. ( Kinuta, M; Maruyama, H; Nakano, H; Naoi, M; Nishibe, S; Oka, Y; Okamura, J; Tachiyama, G; Tane, S; Yayoi, E, 1988)
"In 8 cases of advanced and/or relapsed gastric cancer (7 cases advanced, 1 case relapsed), we undertook combination chemotherapy with systemic administration of cisplatin and celiac arterial infusion of carboquone intermittently under continuous administration of OK-432 i."	1.27	[Clinical study of combination chemotherapy using carboquone, cisplatin, UFT and OK-432 in 7 cases of advanced gastric cancers and a relapsed gastric cancer]. ( Horiuchi, M; Nakarai, I; Nasu, K; Shinoda, A, 1988)
"A 75-year-old man with gastric cancer metastatic to the liver was treated by combined administration of Tegafur (800 mg/body/day), 5-fluorouracil (300 mg/body/day) and Mitomycin C (hepatic arterial infusion of 20 mg/body and intravenous infusion of 8 mg/body)."	1.27	[Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C]. ( Ito, T; Nehashi, Y; Sasaki, J; Sasaki, Y, 1988)
"These findings suggested gallbladder cancer with liver metastasis, and he was soon started on tegafur rectally (1,000 mg/day) and PSK orally (3."	1.27	[Successful treatment with tegafur and PSK in a patient with gallbladder cancer]. ( Komaki, H; Maeda, M; Mihara, K; Nakamura, S; Onizuka, Y; Seita, M, 1988)
"was diagnosed as having gastric cancer with meningeal carcinomatosis and admitted to our hospital in September, 1982."	1.27	[Case report of meningeal carcinomatosis of gastric cancer successfully treated with intrathecal and systemic chemotherapy]. ( Horikoshi, N; Inagaki, J; Inoue, K; Ogawa, M; Takagi, K; Takano, Y; Usui, N, 1985)
"Two patients who had advanced gastric cancer and metastatic liver tumors were treated with a combined chemotherapy using UFT and mitomycin C."	1.27	[A combined chemotherapy with UFT and mitomycin C in advanced gastric cancer; report of 2 cases]. ( Hanawa, S; Hara, S; Joya, K; Nakata, K; Sato, K; Shigemitsu, M, 1985)
"A 35-year-old woman tuffering from gastric cancer associated with disseminated carcinomatosis of the bone marrow is reported."	1.27	[Effective postoperative chemotherapy of gastric cancer associated with disseminated carcinomatosis of the bone marrow]. ( Akimoto, R; Asano, E; Higashino, Y; Kato, M; Mukawa, A; Nagakawa, T; Nakamura, T; Uchida, H, 1985)
" The group of long term administration of FT-207 and CQ included many patients with good response."	1.26	[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer]. ( Fukuda, O; Inoue, S; Maeyama, M; Nakayama, M; Tajima, C; Tokunaga, T, 1982)
"Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2."	1.26	Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study. ( Buroker, T; Groppe, C; Guy, G; Heilbrun, L; Hoogstraten, B; McCracken, J; Padilla, F; Quagliana, J; Vaitkevicius, VK, 1979)
"Fifteen patients with advanced gastric cancer were treated with the combination of Ftorafur, Adriamycin and mitomycin-C (FAM II)."	1.26	A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma. ( Haller, DG; Hoth, DF; MacDonald, JS; Rosenoff, S; Schein, PS; Smythe, T; Woolley, PV, 1979)

Research

Studies (938)

Authors

Clinical Trials (52)

Trial Overview

Trial Outcomes

Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments

Timeframe	Studies, this research(%)	All Research%
pre-1990	119 (12.69)	18.7374
1990's	98 (10.45)	18.2507
2000's	373 (39.77)	29.6817
2010's	331 (35.29)	24.3611
2020's	17 (1.81)	2.80

Authors	Studies
Hirahara, N	1
Matsubara, T	2
Kaji, S	2
Yamamoto, T	5
Hyakudomi, R	1
Takai, K	1
Ishitobi, K	1
Uchida, Y	2
Tajima, Y	1
Lin, JL	1
Lin, JX	1
Lin, JP	1
Zheng, CH	1
Li, P	1
Xie, JW	1
Wang, JB	1
Lu, J	1
Chen, QY	1
Huang, CM	1
Miyata, R	3
Hamaji, M	1
Nakakura, A	1
Morita, S	14
Shimazu, Y	1
Ishikawa, M	2
Kayawake, H	1
Menju, T	1
Sakaguchi, Y	1
Sonobe, M	1
Takahashi, M	14
Aoyama, A	1
Sumitomo, R	1
Huang, CL	1
Kono, T	3
Miyahara, R	2
Matsumoto, A	1
Katakura, H	1
Fukada, T	1
Sakai, H	4
Kobayashi, M	8
Okumura, N	2
Date, N	1
Fujinaga, T	1
Miyamoto, E	1
Nakagawa, T	2
Date, H	3
Yamaguchi, T	14
Takashima, A	4
Nagashima, K	1
Makuuchi, R	1
Aizawa, M	1
Ohashi, M	5
Tashiro, K	2
Yamada, T	13
Kinoshita, T	2
Hata, H	1
Kawachi, Y	5
Kawabata, R	1
Tsuji, T	3
Hihara, J	2
Sakamoto, T	5
Fukagawa, T	2
Katai, H	5
Higuchi, K	5
Boku, N	18
Chen, HW	1
Kuo, HY	1
Chen, BB	1
Tien, YW	1
Kuo, SH	1
Yang, SH	7
Yang, PC	2
Huang, KW	2
Pua, U	2
Kim, MD	2
Li, SP	2
Li, XY	2
Liang, PC	2
Zhang, C	2
Yu, GM	1
Zhang, M	2
Liu, D	2
Wang, X	8
Yang, DP	1
Yotsukura, M	1
Watanabe, S	3
Zong, Y	1
Yuan, J	1
Peng, Z	1
Lu, M	2
Shen, L	3
Zhou, J	1
Haas, S	1
Møller Faaborg, P	1
Brock, C	1
Krogh, K	1
Gram, M	1
Lundby, L	1
Mohr Drewes, A	1
Laurberg, S	1
Christensen, P	1
Ge, YX	1
Lin, YY	1
Bi, QQ	1
Chen, YJ	1
Li, S	2
Sun, Y	2
Li, K	1
Shen, X	1
Xue, Y	1
Liang, P	1
Li, G	3
Chen, L	2
Zhao, Q	1
Fu, W	1
Liang, H	1
Xin, H	1
Suo, J	1
Fang, X	1
Zheng, Z	2
Xu, Z	1
Chen, H	1
Zhou, Y	3
He, Y	1
Huang, H	2
Zhu, L	1
Yang, K	1
Ji, J	1
Ye, Y	1
Zhang, Z	3
Li, F	1
Tian, Y	1
Park, S	1
Miwa, K	4
Oki, E	2
Enomoto, M	1
Ihara, K	1
Ando, K	3
Fujita, F	3
Tominaga, M	2
Mori, S	2
Nakayama, G	1
Shimokawa, M	1
Saeki, H	1
Baba, H	11
Mori, M	12
Akagi, Y	1
Yamaguchi, K	7
Fuse, N	3
Komatsu, Y	12
Fujii, H	4
Hironaka, S	5
Omuro, Y	4
Muro, K	7
Yasui, H	4
Ueda, S	1
Nishina, T	9
Watanabe, M	11
Ohtsu, A	6
Wada, T	4
Yoshikawa, T	18
Sekine, S	2
Kamiya, A	1
Hayashi, T	16
Otsuki, S	1
Yamagata, Y	1
Grieb, BC	1
Agarwal, R	1
Kumagai, T	1
Kimura, M	2
Inoue, T	6
Tamiya, M	1
Nishino, K	1
Imamura, F	1
Sadahiro, S	9
Suzuki, T	13
Tanaka, A	7
Okada, K	13
Saito, G	2
Miyakita, H	1
Ogimi, T	1
Nagase, H	4
Miura, Y	3
Sukawa, Y	1
Nishikawa, K	13
Tokunaga, S	4
Okuda, H	1
Taku, K	3
Moriwaki, T	6
Negoro, Y	1
Kimura, Y	10
Uchino, K	2
Shinozaki, K	2
Shinozaki, H	1
Musha, N	3
Yoshiyama, H	1
Tsuda, T	1
Miyata, Y	2
Sugimoto, N	3
Shirakawa, T	2
Ito, M	2
Yonesaka, K	1
Yoshimura, K	3
Nosho, K	1
Takano, T	2
Hyodo, I	12
Yoshizawa, J	1
Ishizone, S	1
Ikeyama, M	1
Nakayama, J	1
Nakagawa, R	1
Inoue, Y	6
Ohki, T	1
Kaneko, Y	1
Maeda, F	1
Yamamoto, M	8
Takayoshi, K	1
Kusaba, H	4
Uenomachi, M	1
Mitsugi, K	4
Makiyama, C	1
Makiyama, A	1
Shibata, Y	2
Shinohara, Y	1
Inadomi, K	1
Tsuchihashi, K	1
Arita, S	1
Ariyama, H	4
Esaki, T	9
Akashi, K	3
Baba, E	5
Shitara, K	7
Kadowaki, S	3
Sakai, D	2
Yoshikawa, R	4
Piao, Y	1
Ozeki, A	1
Inoue, K	7
Gritli, I	1
Tsuboi, M	3
Hamada, C	5
Kato, H	10
Ohta, M	8
Cheng, YJ	1
Meng, CT	1
Shao, YJ	1
Li, NN	1
Zhou, N	1
Yan, XY	1
Gao, X	1
Zhou, JF	1
Bai, CM	1
Ajani, JA	8
Abramov, M	1
Bondarenko, I	1
Shparyk, Y	1
Gorbunova, V	3
Hontsa, A	1
Otchenash, N	1
Alsina, M	1
Lazarev, S	1
Feliu, J	3
Elme, A	1
Esko, V	1
Abdalla, K	1
Verma, U	1
Benedetti, F	1
Aoyama, T	11
Mizuguchi, H	1
Makris, L	1
Rosati, G	1
Hosokawa, A	1
Ando, T	6
Ogawa, K	2
Ueda, A	1
Yoshita, H	1
Mihara, H	1
Fujinami, H	1
Kajiura, S	2
Yabushita, K	3
Horikawa, N	1
Kobayashi, Y	3
Yoshioka, A	1
Origasa, H	1
Sugiyama, T	3
Fujii, M	12
Masuishi, T	1
Kunisaki, C	6
Matsusaka, S	4
Segawa, Y	2
Nakamura, M	8
Sasaki, K	5
Nagao, N	1
Hatachi, Y	2
Yuasa, Y	3
Asami, S	1
Takeuchi, M	6
Furukawa, H	11
Nakajima, T	11
Fujitani, K	7
Kurokawa, Y	5
Takeno, A	5
Endoh, S	1
Ohmori, T	1
Fujita, J	1
Yamasaki, M	2
Takiguchi, S	3
Doki, Y	6
Nokihara, H	2
Lu, S	1
Mok, TSK	1
Nakagawa, K	7
Yamamoto, N	12
Shi, YK	1
Zhang, L	1
Soo, RA	1
Yang, JC	1
Sugawara, S	2
Nishio, M	3
Takahashi, T	16
Goto, K	2
Chang, J	1
Maemondo, M	1
Ichinose, Y	9
Cheng, Y	2
Lim, WT	1
Tamura, T	5
Yamada, Y	11
Denda, T	3
Gamoh, M	2
Iwanaga, I	3
Yuki, S	5
Shimodaira, H	1
Ohori, H	2
Kobayashi, K	6
Tsuda, M	3
Miyamoto, Y	1
Kotake, M	2
Shimada, K	3
Sato, A	5
Takahashi, S	9
Ishioka, C	2
Winther, SB	1
Bjerregaard, JK	1
Schonnemann, KR	1
Ejlsmark, MW	1
Krogh, M	1
Jensen, HA	3
Pfeiffer, P	5
Wei, J	2
Dong, X	1
Du, F	1
Tang, S	1
Wei, H	1
Ebisui, C	4
Hamano, R	2
Minoji, T	1
Kitahara, T	3
Yanagisawa, T	2
Okamura, S	7
Fukuchi, N	2
Murata, K	3
Yokouchi, H	3
Kinuta, M	3
Ohishi, K	1
Kawamitsu, K	1
Ooshiro, T	1
Nabekura, D	1
Kadoya, K	1
Takagi, R	1
Hiranuma, A	1
Urita, T	1
Yoshida, Y	8
Sato, Y	7
Tanaka, H	3
Nagashima, M	1
Okazumi, S	1
Kato, R	4
Uchiyama, K	1
Katarao, Y	1
Tanaka, R	3
Fuse, T	1
Takemura, M	7
Yamamoto, Y	7
Shimizu, Y	2
Tsukamoto, T	1
Takahama, M	1
Kodai, S	1
Kanazawa, A	2
Hori, T	3
Kaizaki, R	1
Takatsuka, S	1
Komatsu, R	1
Konishi, M	3
Imai, A	1
Sugimoto, K	5
Katakami, N	4
Imai, Y	2
Kamoshida, S	1
Kim, SM	1
An, JY	1
Lee, J	5
Sohn, TS	3
Kim, S	4
Kuroda, J	1
Aoki, H	3
Kondou, N	1
Sumita, T	1
Itoh, K	2
Agawa, S	1
Qiu, YD	1
Song, TQ	1
Wang, Y	5
Cheng, X	1
Cui, YH	1
Hou, J	1
Ji, Y	1
Sun, YH	1
Shen, ZB	1
Liu, FL	1
Liu, TS	1
Yao, T	1
Li, L	2
Pan, C	1
Zhang, N	1
Motoi, F	2
Satoi, S	4
Honda, G	1
Wada, K	3
Shinchi, H	4
Matsumoto, I	3
Sho, M	3
Tsuchida, A	3
Unno, M	3
Sato, T	10
Yoshida, K	14
Yamashita, Y	2
Shirai, Y	2
Ryo, H	1
Ilson, DH	1
Nobori, C	1
Uchima, Y	1
Aomatsu, N	1
Okada, T	6
Miyamoto, H	5
Kurihara, S	1
Wang, E	1
Hirakawa, T	1
Iwauchi, T	1
Morimoto, J	1
Yamagata, S	4
Nakazawa, K	1
Takeuchi, K	2
Shinkai, M	1
Imano, M	2
Chiba, Y	2
Iwama, M	1
Shiraisi, O	1
Yasuda, A	2
Tsubaki, M	1
Nishida, S	1
Yasuda, T	2
Ioka, T	4
Ueno, M	4
Ueno, H	11
Park, JO	5
Chang, HM	4
Sasahira, N	5
Kanai, M	3
Chung, IJ	4
Ikeda, M	15
Nakamori, S	7
Mizuno, N	3
Hara, H	2
Sugimori, K	1
Furuse, J	9
Maguchi, H	3
Furukawa, M	2
Fukuzawa, K	1
Kim, JS	5
Yukisawa, S	1
Okusaka, T	14
Soda, H	1
Ogawara, D	1
Fukuda, Y	1
Tomono, H	1
Okuno, D	1
Koga, S	1
Taniguchi, H	3
Yoshida, M	3
Harada, T	3
Umemura, A	2
Yamaguchi, H	5
Mukae, H	1
Terashima, M	5
Mizusawa, J	3
Nunobe, S	1
Nishida, Y	1
Kaji, M	3
Fukushima, N	5

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer[NCT03636308]	Phase 2	40 participants (Anticipated)	Interventional	2018-07-17	Recruiting
Open-label, Single-arm, Multicenter Phase II Trial Investigating Cetuximab in Combination With S-1 and Cisplatin as First-line Treatment for Patients With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction[NCT01388790]	Phase 2	40 participants (Actual)	Interventional	2011-06-30	Completed
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy[NCT01285557]	Phase 3	361 participants (Actual)	Interventional	2011-04-14	Terminated (stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.)
A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691]	Phase 2/Phase 3	350 participants (Anticipated)	Interventional	2016-10-31	Completed
A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study)[NCT03013010]	Phase 3	682 participants (Anticipated)	Interventional	2016-12-31	Recruiting
A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT05161572]	Phase 2	152 participants (Anticipated)	Interventional	2021-09-28	Recruiting
An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179]	Phase 3	1,053 participants (Actual)	Interventional	2005-05-31	Completed
A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer[NCT00287768]	Phase 3	628 participants (Anticipated)	Interventional	2006-03-31	Completed
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552]	Phase 3	0 participants (Actual)	Interventional	2016-03-31	Withdrawn
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258]	Phase 2/Phase 3	426 participants (Actual)	Interventional	2006-01-31	Completed
A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal Carcinoma. (SHOGUN Trial)[NCT01227239]	Phase 1/Phase 2	45 participants (Anticipated)	Interventional	2010-09-30	Active, not recruiting
The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer[NCT03007446]	Phase 2	20 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842]	Phase 2	0 participants (Actual)	Interventional	2017-10-30	Withdrawn (stopped due to non-accrual)
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529]	Phase 2	28 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Randomized Phase II/III Trial of Second Line Chemotherapy Comparing CPT-11 Monotherapy Versus S-1/CPT-11 Combination for S-1 Refractory Gastric Cancer[NCT00639327]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2008-03-31	Completed
Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620]		100 participants (Anticipated)	Interventional	2023-06-20	Not yet recruiting
A Prospective Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy[NCT00952926]		55 participants (Actual)	Observational	2009-10-31	Completed
DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer[NCT04927897]		50 participants (Anticipated)	Observational	2022-08-16	Recruiting
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866]		58 participants (Anticipated)	Observational	2022-01-01	Enrolling by invitation
A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer[NCT01110941]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2009-09-30	Completed
Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer.[NCT00915382]	Phase 3	625 participants (Actual)	Interventional	2009-01-31	Completed
Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096]	Phase 2	35 participants (Anticipated)	Interventional	2017-02-01	Recruiting
A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer[NCT01198392]	Phase 3	270 participants (Anticipated)	Interventional	2008-09-30	Recruiting
Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)[NCT00498225]	Phase 3	834 participants (Actual)	Interventional	2007-07-31	Completed
Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359]	Phase 3	111 participants (Actual)	Interventional	2014-02-28	Completed
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552]	Phase 3	870 participants (Anticipated)	Interventional	2013-08-19	Recruiting
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]	Phase 2	200 participants (Actual)	Interventional	2015-10-05	Active, not recruiting
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449]	Phase 3	338 participants (Actual)	Interventional	2012-12-31	Completed
Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910]	Phase 1	36 participants (Anticipated)	Interventional	2022-10-31	Recruiting
Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin. Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin and in Combination With Nivolumab in Patients With Peritoneal Carcinomat[NCT03172416]	Phase 1	21 participants (Anticipated)	Interventional	2017-04-12	Recruiting
Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894]	Phase 2	20 participants (Anticipated)	Interventional	2013-01-31	Recruiting
A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407]	Phase 1	27 participants (Actual)	Interventional	2010-11-30	Completed
Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)[NCT00142350]	Phase 3	690 participants	Interventional	2000-11-30	Completed
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer[NCT03700333]	Phase 3	120 participants (Anticipated)	Interventional	2018-10-20	Not yet recruiting
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062]	Phase 1	120 participants (Actual)	Interventional	2013-03-31	Completed
The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398]		54 participants (Anticipated)	Observational	2022-04-30	Not yet recruiting
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618]	Phase 2	41 participants (Actual)	Interventional	2014-07-05	Completed
A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection[NCT02191566]	Phase 2	8 participants (Actual)	Interventional	2015-05-31	Terminated (stopped due to The patient's study enrollment was too low.)
Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer[NCT00569790]	Phase 2	53 participants (Actual)	Interventional	2007-10-31	Completed
PD-1 Antibody Plus Gemcitabine and Oxaliplatin (GEMOX) as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma Patients With Positively Metastatic Lymph Nodes : a Single Arm, Phase II Trial[NCT05430698]	Phase 2	62 participants (Anticipated)	Interventional	2023-01-31	Recruiting
Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer[NCT01375972]	Phase 2	92 participants (Actual)	Interventional	2008-03-31	Completed
The Effect of Postoperative Supplemental Parenteral Nutrition (SPN) in Gastric Cancer Patients Who Underwent Gastrectomy: A Multicenter Prospective Randomized Controlled Trial[NCT04607057]	Phase 4	224 participants (Anticipated)	Interventional	2020-12-22	Recruiting
A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245]	Phase 1/Phase 2	77 participants (Anticipated)	Interventional	2006-08-31	Completed
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer[NCT01874678]		45 participants (Actual)	Interventional	2011-03-31	Completed
A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer[NCT00525005]	Phase 2	44 participants (Actual)	Interventional	2007-08-31	Completed
Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy[NCT00216034]	Phase 3	255 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Study of ORZEL (UFT + Leucovorin) in Elderly (at Least 75 Years Old) Patients With Colorectal Cancer[NCT00004860]	Phase 2	0 participants	Interventional	2000-10-09	Completed
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703]	Phase 2	38 participants (Actual)	Interventional	2005-08-31	Completed
Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291]	Phase 2	30 participants (Anticipated)	Interventional	2013-12-31	Not yet recruiting
Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143]		63 participants (Actual)	Interventional	2016-02-29	Completed
Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer: A Pilot Retrospective Multicenter Cohort Study[NCT03485105]		1,000 participants (Anticipated)	Observational	2017-11-01	Active, not recruiting
A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589]	Phase 3	60 participants	Interventional	2002-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The best overall response rate is defined as the percentage of participants having achieved confirmed complete response plus partial response as the best overall response according to radiological assessments (based on Response Evaluation Criteria in Solid Tumors version 1.0 [RECIST v 1.0] criteria). (NCT01388790)
Timeframe: Evaluations were performed every 6 weeks until disease progression, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)

Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

Intervention	percentage of participants (Number)
Cetuximab Plus Cisplatin Plus S-1	40

The PFS time is defined as the duration from start of treatment until radiological progression (based on RECIST v 1.0 criteria) or death due to any cause within 60 days of the last tumor assessment or start of treatment. Participants without event are censored on the date of last tumor assessment. (NCT01388790)
Timeframe: Time from start of treatment to disease progression, death or last tumor assessment, reported between day of first participant treated, that is July 2011, until cut-off date, (14 August 2012)

Duration of Response (DR)

Intervention	months (Median)
Cetuximab Plus Cisplatin Plus S-1	5.6

Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3

Intervention	months (Median)
S-1+Cisplatin	5.1
5FU+Cisplatin	4.2

An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)

Overall Response Rate (ORR): Percentage of Participants With Overall Response

Intervention	Participants (Count of Participants)
S-1+Cisplatin	157
5FU+Cisplatin	78

ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Overall Survival (OS)

Intervention	percentage of participants (Number)
S-1+Cisplatin	34.7
5FU+Cisplatin	19.8

OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)

Progression-free Survival (PFS)

Intervention	months (Median)
S-1+Cisplatin	7.5
5FU+Cisplatin	6.6

PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)

Time to Treatment Failure (TTF)

Intervention	months (Median)
S-1+Cisplatin	4.4
5FU+Cisplatin	3.9

TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)

Time to Tumor Response (TTR)

Intervention	months (Median)
S-1+Cisplatin	4.2
5FU+Cisplatin	3.8

TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)

Intervention	months (Median)
S-1+Cisplatin	1.8
5FU+Cisplatin	1.9

AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)

Duration of Response (DR)

Intervention	Participants (Count of Participants)
	TEAE	TESAE
5FU+Cisplatin	111	31
S-1+Cisplatin	214	63

Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).

Median Survival

Intervention	Months (Median)
S-1/Cisplatin	6.5
5-FU/Cisplatin	5.8

Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).

Overall Response Rate (ORR)

Intervention	Months (Median)
S-1/Cisplatin	8.6
5-FU/Cisplatin	7.9

The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).

Progression-free Survival (PFS)

Intervention	Percentage of patients in each group (Number)
S-1/Cisplatin	29.1
5-FU/Cisplatin	31.9

The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.

Time to Treatment Failure (TTF)

Intervention	Months (Median)
S-1/Cisplatin	4.8
5-FU/Cisplatin	5.5

The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.

Median Overall Survival Will be Determined.

Intervention	Months (Median)
S-1/Cisplatin	3.8
5-FU/Cisplatin	3.8

Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years

Number of Participants With Acute Toxicities Following SBRT

Intervention	months (Median)
Combination of Cyberknife With S-1	14.4

The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT

Number of Participants With Late Toxicities Following SBRT

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	9

The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT

One-year Overall Survival Rate

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	5

One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year

The Median Progression Free Survival Time Will be Determined.

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	46

Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years

The Quality of Life Will be Analyzed.

Intervention	months (Median)
Combination of Cyberknife With S-1	10.1

The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years

Intervention	units on a scale (Mean)
	Global health status	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Fatigue	Nausea and vomiting	Pain	Dyspnea	Insomnia	Appetite loss	Constipation	Diarrhea	Financial difficulties
Combination of Cyberknife With S-1	50.0	64.2	54.8	68.5	73.8	74.6	46.7	55.3	48.7	9.5	19.0	59.2	13.2	13.7	31.2

tegafur and Adenocarcinoma

Research Excerpts

Research

Studies (938)

Authors

Clinical Trials (52)

Trial Overview

Trial Outcomes

Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments

Median Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

Duration of Response (DR)

Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3

Overall Response Rate (ORR): Percentage of Participants With Overall Response

Overall Survival (OS)

Progression-free Survival (PFS)

Time to Treatment Failure (TTF)

Time to Tumor Response (TTR)

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)

Duration of Response (DR)

Median Survival

Overall Response Rate (ORR)

Progression-free Survival (PFS)

Time to Treatment Failure (TTF)

Median Overall Survival Will be Determined.

Number of Participants With Acute Toxicities Following SBRT

Number of Participants With Late Toxicities Following SBRT

One-year Overall Survival Rate

The Median Progression Free Survival Time Will be Determined.

The Quality of Life Will be Analyzed.

Reviews

Trials

Other Studies

Article	Year
S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. Medicine, 2020, Volume: 99, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junc	2020
Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature. Medicine, 2020, Volume: 99, Issue:3 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Hu	2020
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. Current treatment options in oncology, 2021, 08-23, Volume: 22, Issue:10 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C	2021
Gastric hepatoid adenocarcinoma resulting in a spontaneous gastric perforation: a case report and review of the literature. BMC cancer, 2017, 05-25, Volume: 17, Issue:1 Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Drug Combination	2017
[A Case of Recurrent Rectal Cancer with Adrenal and Lung Metastasis with More than Ten-Year Survival after Surgery]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Chemotherap	2017
Advances in the treatment of gastric cancer. Current opinion in gastroenterology, 2018, Volume: 34, Issue:6 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C	2018
Adjuvant therapy of pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Humans;	2013
Second-line therapy in pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant	2013
[Gastrectomy for a patient with advanced gastric cancer with spleen metastases following induction chemotherapy with S-1 plus cisplatin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female	2014
Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer? Surgery today, 2015, Volume: 45, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality	2015
[A case report of distal gastrectomy with thrombectomy after NAC for Gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations;	2014
[A Case of HER2-Positive Advanced Gastric Cancer with a Pathological Complete Response to Neoadjuvant Chemotherapy with S-1/CDDP/Trastuzumab]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastre	2015
[Long-Term Disease-Free Survival through Postoperative Chemotherapy in a Case of Gastric Cancer with Peritoneal Dissemination]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doceta	2015
A case of metachronous liver metastasis from neuroendocrine carcinoma of the stomach at 1 year and 10 months after endoscopic submucosal dissection. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2017, Volume: 114, Issue:2 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Neuroendocrine; Chemotherapy, Adju	2017
[Persistent Chemotherapy-Induced Hiccups Successfully Treated with Pregabalin]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; D	2017
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:9 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ca	2008
Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:12 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung	2009
[A case of advanced gastric cancer responding completely treated with S-1 therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Drug Combinations; Gastrectomy; Humans; Male; Middl	2009
Aggressive recurrence of gastric cancer as a granulocyte-colony-stimulating factor-producing tumor. International journal of clinical oncology, 2010, Volume: 15, Issue:2 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Drug Combinations;	2010
[A case of Stage IV AFP producing gastric cancer with long-term survival treated by adjuvant chemotherapy with S-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3 Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Cardia; Chemotherapy, Adj	2010
Meta-analysis of late course accelerated hyperfractionated radiotherapy combined with FP chemotherapy for esophageal carcinoma. Chinese journal of cancer, 2010, Volume: 29, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchitis; Carcinoma, Squamous Cell	2010
[Two cases of the primary small intestine cancer successfully treated with S-1 and UFT/LV therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol	2010
[A case report of primary duodenal adenocarcinoma responding to chemotherapy with S-1 and irinotecan]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther	2011
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future oncology (London, England), 2011, Volume: 7, Issue:6 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap	2011
[A case of drug-induced eosinophilic pneumonia due to tegafur-uracil(UFT®)]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:10 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Female	2011
[Locally recurrent case of gastric cancer with serosal invasion after four months of endoscopic submucosal dissection]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Endos	2012
[Advanced gastric cancer successfully treated by TS-1--case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Aorta, Abdominal; Combined Modality Therapy;	2004
[Evaluation of pre-operative administration of TS-1 in patients with advanced gastric or colorectal cancer--estimation of pathological effectiveness for postoperative adjuvant chemotherapy with TS-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms;	2005
Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous	2005
[Adjuvant chemotherapy for non-small cell lung cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem	2006
Chemotherapy of advanced gastric cancer. Cancer treatment reviews, 2007, Volume: 33, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;	2007
Medical treatment for advanced gastroesophageal adenocarcinoma. Current opinion in gastroenterology, 2007, Volume: 23, Issue:6 Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit	2007
[Moderately differentiated adenocarcinoma of the rectum: a case report of remarkable response to preoperative administration of FT suppository]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonoscopy; Combined Modality Therapy; Humans; Mal	1997
Knuckle pad-like keratoderma: a new cutaneous side reaction induced by tegafur. International journal of dermatology, 1998, Volume: 37, Issue:4 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Gallbladder Neoplasms; Humans; Keratoderma, P	1998
[A noteworthy case of postoperative liver metastasis from gastric cancer which responded well to UFT therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:11 Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Gastrect	2000
[A case of advanced prostatic cancer in a 44-year-old treated effectively with combination chemo-endocrine therapy]. Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:4 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality	1990
[Effect of tegafur administration combined with hormonal therapy in patients with newly diagnosed stage D prostatic cancer]. Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:7 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Humans; Ma	1990
[A case of advanced gastric cancer (Borrmann's type 2) that disappeared following short-term preoperative chemotherapy with UFT]. Gan no rinsho. Japan journal of cancer clinics, 1989, Volume: 35, Issue:8 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Gastrecto	1989